 
 
 
 
Immune  
Tolerance 
Network 
 
 
Anti-TSLP (AMG 157) plus antigen-specific immunotherapy for 
induction of tolerance in individuals with cat allergy 
 Protocol ITN057AD 
Version 6.0 (August 14, 2017) 
IND # 117,[ADDRESS_1123960]., Suite 280 
Los Angeles, CA [ZIP_CODE] 
Tel: [PHONE_16916]    Fax: [PHONE_16917]     
Email: [EMAIL_15412]  
 
ITN Clinical Trial Physician 
Srinath Sanda, MD 
Clinical Trial Physician 
Clinical Trials Group 
Immune Tolerance Network 
[ADDRESS_1123961] 
San Francisco, CA [ZIP_CODE] 
Tel: [PHONE_1888] Fax: [PHONE_11444] 
Email: [EMAIL_1612] NIAID Medical Monitor 
Lisa M. Wheatley, MD, MPH 
Medical Officer, Section Chief, 
Allergy, Asthma and Airways Biology Branch 
Division of Allergy, Immunology,  and 
Transplantation  
National Institute of Allergy and Infectious 
Diseases 
[ADDRESS_1123962] Rm 6B56 
Rockville, MD, [ZIP_CODE]  
Tel: [PHONE_16918]     Fax:  [PHONE_16919] 
Email: [EMAIL_15413] 
 
ITN Clinical Operations Manager 
Rachel Yan 
Clinical Operations Manager 
Clinical Trials Group 
Immune Tolerance Network 
[ADDRESS_1123963] 
San Francisco, CA [ZIP_CODE] 
Tel: 415-353- 4425     Fax: [PHONE_11444] 
Email: [EMAIL_1615]   
 NIAID Project Manager 
Joy Laurienzo Panza, RN, BSN 
NIAID Project Manager 
Division of Allergy, Immunology, and 
Transplantation 
National Institute of Allergy and Infectious 
Diseases 
[ADDRESS_1123964] Rm 6B51 
Rockville, MD [ZIP_CODE] 
Tel: [PHONE_1894]  Fax: [PHONE_16920] 
Email: [EMAIL_1617]  
  
 
  
 
Protocol ITN057AD  Version 6.[ADDRESS_1123965] 14, 2017 
Anti-TSLP and cat immunotherapy 
  
ITN Associate Director, Biomarker & 
Discovery Research  
David Larson, PhD 
Biomarker & Discovery Research 
Immune Tolerance Network 
[ADDRESS_1123966] 
Bethesda, MD [ZIP_CODE]  
Tel: [PHONE_1890]     Fax: [PHONE_16921] 
Email: [EMAIL_1614]    NIAID Regulatory Officer 
Maria Veri, PhD 
Regulatory Officer 
Division of Allergy, Immunology, and Transplantation  
National Institute of Allergy and Infectious Diseases 
[ADDRESS_1123967] 7B48, MSC9828 
Rockville, MD [ZIP_CODE] 
Tel: [PHONE_2184]     Fax: [PHONE_11450] 
Email: [EMAIL_1867]  
 
Rho Scientist 
Michelle Sever, PhD 
Senior Research Scientist 
Rho Inc. 
[ADDRESS_1123968] 
Chapel Hill, NC [ZIP_CODE]  
Tel: [PHONE_1892] 
Fax [PHONE_1893] 
Email: [EMAIL_1616] 
  
Rho Biostatistician 
Miguel Villarreal, M.S. 
Senior Biostatistician 
Rho Inc. 
[ADDRESS_1123969] 
Chapel Hill, NC [ZIP_CODE]  
Tel: [PHONE_16922] 
Fax [PHONE_1893] 
Email: [EMAIL_15414] 
 
This clinical study is supported and conducted by [CONTACT_80910], which is 
sponsored by [CONTACT_80911]. 
This document is confidential. It is provided for review only to investigators, potential 
investigators, consultants, study staff, and applicable independent ethics committees or institutional 
review boards. It is understood that the contents of this document will not be disclosed to others 
without written authorization from ITN and NIAID unless it is necessary to obtain informed consent 
from potential study participants.  
 
 
 
 
 
 
 
 
 
 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1123970] 14, 2017 
Anti-TSLP and cat immunotherapy 
  
 
Protocol Approval 
 
 Trial ID:  ITN057AD  Protocol Version: 6.0 
Date:  August 14, 2017 
IND # 117,529 Protocol Chair:  Jonathan Corren, MD  
 
Title:     Anti-TSLP (AMG 157) plus antigen-specific immunotherapy for induction of tolerance in 
individuals with cat allergy  
I confirm that I have read the above protocol in the latest version. I understand it, and I will 
work according to the principles of good clinical practice (GCP) as described in the US Code of 
Federal Regulations (CFR)—45 CFR part 46 and 21 CFR parts 50, 56, and 312, and in the 
International Conference on Harmonization (ICH) document Guidance for Industry: E6 Good 
Clinical Practice: Consolidated Guidance  dated April 1996. Further, I will conduct the study in 
keepi[INVESTIGATOR_331522]. 
 
As the principal investigator, I agree to carry out the study by [CONTACT_93216]. 
 
      By [CONTACT_276688], investigators and their designees also agree to: 
i) Use AMG 157 and placebo for AMG 157 only in accordance with the Protocol and for 
no other Purpose 
ii) Not transfer AMG 157 or Placebo for AMG 157 to any parties other than the 
Distributor identified by [CONTACT_811664]) Not chemically modify, replicate, make derivatives of, or reverse engineer AMG 157 or 
Placebo for AMG 157 
 
 
__________________________________________                                        
Principal Investigator                        ( Print)                     
 
 
__________________________________________         _________________ 
Principal Investigator                        ( Sign)                      Date 
 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1123971] 14, 2017 
Anti-TSLP and cat immunotherapy 
 Table of Contents 
1 BACKGROUND AND RATIONALE  ................................................................................ 17  
1.1 CAT ALLERGY AS A CLINICAL PROBLEM  ................................................................ 17  
 Overview ................................................................................................................................... 17  
 Current Approaches to Cat Allergy ........................................................................................... 17  
 Clinical Outcomes with Subcutaneous Cat Dander Immunotherapy ........................................ 17  
 Mechanisms of Allergen-specific Immunotherapy ................................................................... 18  
 Why New Approaches are Needed ........................................................................................... 19  
1.2 THYMIC STROMAL LYMPHOPOIETIN (TSLP)  ............................................................ 19  
 Role in Immune Responses ....................................................................................................... 19  
 Role in Asthma ......................................................................................................................... 20  
 Role in Allergic Rhinitis ........................................................................................................... 20  
1.3 TSLP INHIBITION  ......................................................................................................... 20  
 Principle .................................................................................................................................... 20  
 AMG 157 .................................................................................................................................. 20  
1.4 COMBINATION OF IMMUNOTHERAPY WITH TSLP INHIBITION  ............................. 21  
 Combining Antigen with an Immunomodulatory Agent ........................................................... 21  
 Why the Combination Might Lead to Long-lasting Effects or Tolerance ................................. 22  
1.5 TRIAL DESIGN .............................................................................................................. 22  
 Overview ................................................................................................................................... 22  
 Why Total Nasal Symptom Score (TNSS) was Chosen as an Endpoint ................................... 23  
 Why a Tolerance Trial .............................................................................................................. 23  
 Why Cat Dander as an Allergen for Study ................................................................................ 24  
 Mechanistic Questions: Overview ............................................................................................ [ADDRESS_1123972] 14, 2017 
Anti-TSLP and cat immunotherapy 
 
 Dose and Schedule .................................................................................................................... 27  
 Interim Analysis ........................................................................................................................ 29  
3.2 STUDY DURATION  ...................................................................................................... 29  
3.3 STUDY ENDPOINTS  ..................................................................................................... 29  
 Primary Endpoint ...................................................................................................................... 29  
 Secondary Endpoints................................................................................................................. 29  
 Exploratory Endpoints .............................................................................................................. 30  
3.4 STOPPI[INVESTIGATOR_16442]  ......................................................................................................... 30  
 Ongoing Review ....................................................................................................................... 30  
 Stoppi[INVESTIGATOR_811617] .......................................................................................................... 30  
3.5 DEFINITION OF HIGH AND LOW EXPOSURE TO CAT ALLERGEN  ........................... 31  
4 ELIGIBILITY  ................................................................................................................... 31  
4.1 INCLUSION CRITERIA  ................................................................................................. 31  
4.2 EXCLUSION CRITERIA  ................................................................................................ 32  
4.3 PREMATURE TERMINATION OF A PARTICIPANT FROM THE STUDY  ..................... 34  
5 STUDY MEDICATIONS  ................................................................................................... 34  
5.1 INVESTIGATIONAL MEDICATION - AMG 157 AND PLACEBO  .................................. 34  
 Formulation and Packaging....................................................................................................... 34  
 Dosage, Preparation, and Administration ................................................................................. 35  
 Recommended Storage Conditions ........................................................................................... 35  
5.2 INVESTIGATIONAL MEDICATION – CAT IMMUNOTHERAPY AND PLACEBO  ........ [ADDRESS_1123973] 14, 2017 
Anti-TSLP and cat immunotherapy 
 6.2 RANDOMIZATION, BLINDING, AND UNBLINDING  ................................................... 40  
 Randomization and Stratification .............................................................................................. 40  
 Blinding .................................................................................................................................... 40  
 Unblinding ................................................................................................................................ 40  
6.3 GENERAL ASSESSMENTS  ........................................................................................... 41  
6.4 CLINICAL ALLERGY ASSESSMENTS  .......................................................................... 41  
 Overview and Washout Periods ................................................................................................ 41  
 Nasal Allergen Challenges ........................................................................................................ 42  
 Skin Testing .............................................................................................................................. 43  
6.5 CLINICAL LABORATORY ASSESSMENTS  .................................................................. 43  
6.6 PHARMACOKINETIC AND AMG 157 NEUTRALIZING ANTIBODY TESTING  ........... 44  
7 TOLERANCE ASSAYS  ..................................................................................................... 44  
7.1 RATIONALE FOR IMMUNE STUDIES  .......................................................................... 44  
7.2 HYPOTHESES TO BE TESTED  ...................................................................................... 45  
7.3 RETENTION OF SAMPLES  ........................................................................................... 46  
7.4 LOCAL IMMUNE RESPONSES IN NASAL MUCOSA  ................................................... 46  
7.5 WHOLE BLOOD ASSAYS  ............................................................................................. 48  
 DNA-HLA Genotypes and Single Nucleotide Polymorphisms ................................................ 48  
 Gene Expression Profiling ........................................................................................................ 48  
7.6 CELL ASSAYS ............................................................................................................... 48  
7.6.1 PBMC Preparation ......................................................................................................................... 48  
7.6.2 Cellular Assays ............................................................................................................................... 49  
7.7 SERUM ASSAYS  ........................................................................................................... 50  
8 ADVERSE EVENTS  .......................................................................................................... 50  
8.1 OVERVIEW  ................................................................................................................... 50  
8.2 DEFINITIONS  ................................................................................................................ 51  
 Adverse Event ........................................................................................................................... 51  
 Study-Specific Adverse Events ................................................................................................. 51  
 Suspected Adverse Reaction and Adverse Reaction ................................................................. 52  
 Serious Adverse Event .............................................................................................................. 53  
 ‘Expected’ versus ‘Unexpected’ Suspected Adverse Reaction ................................................. [ADDRESS_1123974] 14, 2017 
Anti-TSLP and cat immunotherapy 
 8.4.1 Grading Criteria ........................................................................................................................ 55  
8.4.2 Attribution Definitions .............................................................................................................. 56  
8.5 REPORTING SERIOUS ADVERSE EVENTS  .................................................................. 57  
8.5.1 Reporting SAEs to the IND Sponsor......................................................................................... 57  
8.5.2 Reporting SAEs to Health Authorities ...................................................................................... 57  
8.5.3 Reporting SAEs to the DSMB .................................................................................................. 58  
8.5.4 Reporting Pregnancy ................................................................................................................. 58  
9 STATISTICAL CONSIDERATIONS AND ANALYTICAL PLAN  ................................... 59  
9.1 ANALYSIS SAMPLES  ................................................................................................... 59  
9.2 ANALYSIS OF ENDPOINTS  .......................................................................................... 59  
9.2.1 Overview ................................................................................................................................... 59  
9.2.2 Primary Endpoint ...................................................................................................................... 59  
9.2.3 Secondary Endpoints................................................................................................................. 60  
9.2.4 Exploratory Endpoints .............................................................................................................. 60  
9.2.5 Interim Analysis ........................................................................................................................ 60  
9.2.6 Safety Analysis ......................................................................................................................... 61  
9.2.7 Medical History ........................................................................................................................ 62  
9.2.8 Use of Medications ................................................................................................................... 62  
9.3 SAMPLE SIZE ................................................................................................................ 62  
9.4 MISSING DATA ............................................................................................................. 63  
9.5 REPORTING DEVIATIONS FROM THE ORIGINAL STATISTICAL PLAN  ................... 64  
10 ACCESS TO SOURCE DATA/DOCUMENTS  .................................................................. 64  
11 QUALITY CONTROL AND QUALITY ASSURANCE  ..................................................... 64  
12 ETHICAL CONSIDERATIONS AND COMPLIANCE WITH GOOD CLINICAL 
PRACTICE  .................................................................................................................. 65  
12.1 STATEMENT OF COMPLIANCE  ................................................................................... 65  
12.2 INFORMED CONSENT  .................................................................................................. 65  
12.3 PRIVACY AND CONFIDENTIALITY  ............................................................................ 66  
13 PUBLICATION POLICY  .................................................................................................. 66  
14 REFERENCES  .................................................................................................................. 67  
APPENDIX 1 SCHEDULE OF EVENTS:  SCREENING AND UPDOSING  .................................. 69  
APPENDIX 2 SCHEDULE OF EVENTS:  MAINTENANCE  ........................................................ 71  
APPENDIX 3 SCHEDULE OF EVENTS:  OBSERVATION  ......................................................... 73  
APPENDIX 4: WORLD ALLERGY ORGANIZATION SUBCUTANEOUS IMMUNOTHERAPY 
SYSTEMIC REACTION GRADING SYSTEM  ............................................................... [ADDRESS_1123975] 14, 2017 
Anti-TSLP and cat immunotherapy 
  
Table of Tables 
Table 1:  Schedule of cluster immunotherapy injections ......................................................................... 37  
Table 2: Medication washout periods ...................................................................................................... 42  
Table 3: Grading of local reactions to cat immunotherapy and to study procedures ............................... 52  
Table 4: Attribution of adverse events .................................................................................................... 56  
Table 5: Sample size estimates based on pi[INVESTIGATOR_811618] ............................................................. 63  
 
 
Table of Figures 
Figure 1: Screening, allergen challenge, random assignment, treatment, and observation ..................... 28  
Figure 2: Th [ADDRESS_1123976] 14, 2017 
Anti-TSLP and cat immunotherapy 
  
Synopsis 
 
Title 
 Anti-TSLP plus antigen-specific immunotherapy for induction of 
tolerance in individuals with cat allergy 
IND Sponsor NIAID 
Conducted by [CONTACT_811665](s)  Jonathan Corren, MD 
Accrual Objective [ADDRESS_1123977] or 
placebo will be administered subcutaneously with a cluster dose and 
schedule currently in widespread use in the clinical practice of allergy 
in the [LOCATION_002]. There will be an up-dosing period 
(approximately 12 weeks) during which small doses are gradually 
increased to a maintenance dose. Dosing levels may be individually 
tailored based on subject response. The combined up-dosing and 
maintenance periods will total 48 weeks.  
Study Duration Total study duration will be 154 weeks: 
 Study enrollment to occur over 46 weeks. 
 Individual subject study participation will be [ADDRESS_1123978] 14, 2017 
Anti-TSLP and cat immunotherapy 
 Primary Endpoint Total nasal symptom score (TNSS) AUC from 0 to 1 hour after cat 
allergen challenge at 104 weeks. TNSS is calculated with a scale of 0 
to 3 on the 4 parameters of sneezing, rhinorrhea, nasal congestion and 
blockade, and pruritus. Maximum score is 12 
Secondary 
Endpoints Other measures of allergic response including: 
 Skin prick test endpoint titration at baseline, 1, 4, 12, 26, 52, 
78, 104 weeks. 
 Skin early phase response (EPR) to intradermal testing at 
baseline, 26, 52, 104 weeks. EPR is the skin response at 15 
minutes. 
 Skin late phase response (LPR) to intradermal testing at 
baseline, 26, 52, 104 weeks. LPR is the skin response at 6 
hours. 
 Peak TNSS EPR at baseline, 26, 52, 78, [ADDRESS_1123979] value recorded between 0 and 1 hour inclusive 
 TNSS EPR at baseline, 26, 52, 78, 104 weeks. EPR is the 
TNSS AUC from 0 to 1 hour. 
 TNSS LPR at baseline, 26, 52, and 104 weeks. LPR is the 
TNSS AUC from 5 to 6 hours. 
 Peak nasal inspi[INVESTIGATOR_10229] (PNIF) LPR AUC at baseline, 
26, 52, 104 weeks.  LPR is the PNIF AUC from5 to 6 hours. 
 PNIF EPR AUC at baseline, 26, 52, 78, [ADDRESS_1123980] meet all of the following criteria to be eligible for this 
study: 
1. Age 18-65 years. 
2. Removed in protocol version 4.0. 
3. History of moderate-severe allergic rhinitis (AR) caused by 
[CONTACT_811666] [ADDRESS_1123981].  
5. Removed in protocol version 3.0. 
6. Screening nasal allergen challenge in which: 
 TNSS is less than or equal to 3 after the 0 
concentration (vehicle control only) dose, 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1123982] 14, 2017 
Anti-TSLP and cat immunotherapy 
  TNSS increase is less than or equal to 1 
from the TNSS prior to allergen 
administration to the TNSS after the 0 
concentration (vehicle control only) dose, 
 TNSS is greater than or equal to [ADDRESS_1123983] 
dose, 
 Between the first non-zero dose and [ADDRESS_1123984] dose, either: 
 3 or more sneezes are counted or 
 Greater than 20% drop in PNIF is 
recorded. 
7. Body mass index (BMI) is greater or equal to 18.0 and less 
than or equal to 35.0 kg/m2, at screening. 
8. Clinically acceptable physical examination and 
electrocardiogram (ECG) results (12-lead reporting RR, 
PR, QRS, QT and QTcF) prior to Day 0 based on the 
opi[INVESTIGATOR_871]. 
9. Adequate renal function defined as CrCl greater than 80 
mL/min using the Cockcroft Gault equation. 
10. For women of childbearing age, a willingness to use a 
highly effective form of contraception for four months after 
last dose of study medication. Highly effective methods of 
birth control include abstinence, vasectomy by [CONTACT_811667], or a condom with spermicide in combination with 
either hormonal birth control, IUD or barrier methods used 
by [CONTACT_29619]. 
11. For men with female partners of childbearing potential, 
agreement not to donate sperm and to inform their female 
partner of their participation in this clinical study and use 
highly effective methods of birth control for four months 
after last dose of study medication. Highly effective 
methods of birth control include abstinence, vasectomy, or 
a condom with spermicide in combination with either 
hormonal birth control, IUD or barrier methods used by [CONTACT_811668]. 
12. The ability to give informed consent and comply with study 
procedures.   
13. Not currently taking and, for the duration of the study, 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1123985] 14, 2017 
Anti-TSLP and cat immunotherapy 
 agreement not to take any form of immunotherapy, 
including sublingual, subcutaneous or investigational 
immunotherapy. 
Exclusion Criteria Patients who meet any of the following criteria will not be eligible 
for this study: 
1. Removed in protocol version 4.0. 
2. Prebronchodilator FEV1 less than 80% of predicted value at 
screening visit. 
3. Removed in protocol version 3.0.  
4. History of asthma meeting the NAEPP EPR3 classification 
of mild-persistent or worse  in the past year, other than with 
cat exposure, requiring regular inhaled corticosteroids for 
greater than 4 weeks per year. 
5. History of serious chronic medical conditions which might 
interfere with treatment or assessments. 
6. History of emergency visit or hospi[INVESTIGATOR_811619] 12 months. 
7. History of chronic obstructive pulmonary disease (COPD). 
8. History of significant recurrent acute sinusitis, defined as [ADDRESS_1123986] resolved.  
13. High risk of parasitic disease as judged by [CONTACT_093]. 
14. Positive QuantiFERON® tuberculin test unless the potential 
subject has been treated with appropriate chemoprophylaxis.  
15. Exposure to an individual with active tuberculosis within 
six months from randomization. 
16. Subjects tested positive for HIV antibody, Hep B surface 
antigen, or Hep C antibody. 
17. Removed in protocol version 3.0. 
18. History of malignancy of any type , including basal cell and 
squamous cell cancers of the skin, within [ADDRESS_1123987] year or a history of greater than 
or equal to 10 pack years. 
20. Previous immunotherapy treatment with cat allergen within 
the previous 10 years. 
21. Any history of grade 4 anaphylaxis due to any cause as 
defined by [CONTACT_811669]. 
22. History of bleeding disorders or treatment with 
anticoagulation therapy. 
23. Treatment with omalizumab within 6 months prior to 
randomization. 
24. Currently taking any of the following medications:  beta 
blockers; tricyclic antidepressants; monoamine oxidase 
inhibitors; or anti-IgE monoclonal antibody treatment. 
25. Ongoing systemic immunosuppressive treatment. 
26. History of intolerance to the study therapy, rescue 
medications, or their excipi[INVESTIGATOR_840]. 
27. For women of childbearing age a positive serum or urine 
pregnancy test with sensitivity of less than 50 mIU/mL 
within [ADDRESS_1123988] 14, 2017 
Anti-TSLP and cat immunotherapy 
 investigational device within 30 days or five half-lives 
(whichever is longer) prior to randomization.   
29. The presence of any medical condition that the investigator 
deems incompatible with participation in the trial. 
 
  
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1123989] 
ITN Immune Tolerance Network 
LPR late phase reaction 
MedDRA Medical Dictionary for Regulatory Activities 
NAC nasal allergen challenge 
NCI-CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events (version 
4.03, June 14, 2010 ) 
NIAID National Institute of Allergy and Infectious Diseases 
NIH National Institutes of Health 
PD pharmacodynamics 
PK pharmacokinetics 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1123990] 14, 2017 
Anti-TSLP and cat immunotherapy 
 1 B ACKGROUND AND RATIONALE  
1.1 CAT ALLERGY AS A CLINICAL PROBLEM 
 Overview 
Sensitization to cats is a common contributor to nasal allergy symptoms in the United 
States. The 2005-2006 NHANES survey demonstrated that approximately 28% of 
current hay fever sufferers had IgE to cat extract.1  Cat allergen exposure is also a 
widespread issue, with as many as 33% of homes in the [LOCATION_002] having a pet 
cat (Humane Society of [LOCATION_002], 2011). Cat dander allergens have also been 
shown to exist in significant quantities in public buildings [ADDRESS_1123991] available therapi[INVESTIGATOR_014] 
(including omalizumab) inhibiting cat-induced decreases in FEV1 by [CONTACT_3450] 
50%.[ADDRESS_1123992] has been shown 
to effectively reduce symptoms in 3 studies. Alvarez-Cuesta et al. performed a 
double-blind trial of cat dander immunotherapy (containing 13.2 mcg of Fel d 1) for 
[ADDRESS_1123993] 
(containing 15 mcg of Fel d 1) in a controlled trial of 28 patients for 3 months. The 
actively treated group showed significant reductions in symptoms induced by [CONTACT_811670] (mean score 61.6 vs. 17.1) with no change in the placebo group (64.7 
vs. 62.1).[ADDRESS_1123994] study, patients with cat 
allergy received either cat dander immunotherapy (at a dose of 17.3 mcg of Fel d 1) 
or placebo for [ADDRESS_1123995] 14, 2017 
Anti-TSLP and cat immunotherapy 
 significantly after 1 year and continued to improve during the next 2 years compared 
with placebo.  
Two more recent studies attempted to identify whether high doses of cat dander 
immunotherapy has greater immunologic and clinical effects than lower doses. 
Ewbank et al. examined the efficacy of cat immunotherapy in a placebo-controlled 
trial.10 Escalating doses were given in 8 visits over a 4-week period to a target 
maintenance dose of 0 (placebo), 0.6, 3.[ADDRESS_1123996] maintenance dose. The concentration of antigen needed to generate an 
immediate 5 mm wheal was increased in the dose groups with 3.0 or 15 micrograms. 
Nasal allergen challenge thresholds were not increased. These data indicate that 
detectable responses to subcutaneous immunotherapy can be detected as early as five 
weeks after starting therapy. 
The same group performed a similar small trial (N = 26 evaluable) with longer 
follow-up to examine the impact of extended treatment.[ADDRESS_1123997] 14, 2017 
Anti-TSLP and cat immunotherapy 
 The time course of effects of immunotherapy varies according to the immune 
measure:  late phase skin responses are suppressed after as little as two weeks of 
therapy whereas clinical symptoms require 2-3 months for a reduction in severity. 
Less is known about the corresponding mechanisms after cat immunotherapy. 
Ewbank et al. and Nanda et al. both reported approximately two to three-fold 
increases in cat-specific IgG4 after as little as 5 weeks of subcutaneous 
immunotherapy.10,11 In one report there was a decrease in CD4/IL-4-positive (Th 2-
like) cells10 but this has not been a consistent finding.[ADDRESS_1123998] agents 
such as specific cytokine inhibitors. 
1.2 THYMIC STROMAL LYMPHOPOIETIN (TSLP) 
 Role in Immune Responses 
Thymic stromal lymphopoetin is an IL-7-like cytokine discovered in thymic stromal 
cell supernatents originally found to support B cell development.16 It is largely 
produced by [CONTACT_14198][INVESTIGATOR_811620]-allergic inflammation. The TSLP receptor complex comprises the 
TSLP-binding chain (TSLP-R) and the IL-7R-alpha chain. The receptor is expressed 
on dendritic cells, T cells, B cells, mast cells, and NKT cells. Although originally 
recognized as a B cell factor, it acts on a variety of cell types to promote 
inflammation.16,[ADDRESS_1123999] a role in allergic asthma. In a study in 
two cohorts of 36 and 16 subjects with mild to severe asthma, Shikotra et al. reported 
an increase in expression of TSLP protein primarily in epi[INVESTIGATOR_811621]; increased TSLP levels were associated with expression of other Th 2-
related genes.[ADDRESS_1124000] populations, supporting a role for TSLP in the pathogenesis 
of allergic rhinitis.24 
1.3 TSLP INHIBITION 
 Principle 
Preclinical data indicate inhibition of TSLP may block immune-mediated responses 
in an animal model of allergic skin inflammation.25 Zhang et al. examined TSLP 
inhibition in a murine model of allergic asthma. They found an inhibitor comprising a 
soluble TSLP receptor-immunoglobulin molecule reduced inflammatory cell 
infiltrates, and levels of Th 2 cytokines, IL-4 and IL-5, were also reduced in 
bronchoalveloar lavage fluid.26 TSLP is involved in disease pathogenesis in a murine 
model of allergic rhinitis induced by [CONTACT_811671]. In this model neutralizing TSLP antibody 
administered during the mucosal challenge phase after intraperitoneal sensitization 
inhibited allergic inflammation in the nasal mucosa.22 These studies support the 
examination of TSLP inhibition in human allergic disease. 
 AMG 157 
[IP_ADDRESS] Name [CONTACT_811702]-TSLP agent is referred to as AMG 157 with 
[COMPANY_010], Inc. as the manufacturer. In 2012, MedImmune partnered with [COMPANY_010] on 
AMG 157 and as a result the agent can also be identified as MEDI9929/AMG 157. 
 
http://www.amgen.com/media/media_pr_detail.jsp?year=2012&releaseID=1679295   
http://www.medimmune.com/research/pi[INVESTIGATOR_811622] [ADDRESS_1124001] 14, 2017 
Anti-TSLP and cat immunotherapy 
 [IP_ADDRESS] Description and Previous Experience 
The following information has been obtained from the [COMPANY_010] Investigator’s 
Brochure for MEDI19929/AMG 157. 
AMG [ADDRESS_1124002] TSLP expressed in a 
Chinese hamster ovary cell line (Investigator’s Brochure for MEDI9929/AMG 157). 
The molecule is a heterotetramer consisting of two heavy chains of the IgG2 subclass 
and two light chains of the lambda subclass, which are covalently linked through 
disulfide bonds. The antibody binds with high affinity to human and cynomolgus 
TSLP. It inhibits TSLP-induced STAT5 phosphorylation in human dendritic cells. It 
does not bind to mouse TSLP. 
AMG 157 has been assessed in four completed phase I pharmacokinetic trials in 
healthy subjects and in individuals with atopic dermatitis, and mild atopic asthma. It 
is currently (September 2015) being assessed by [CONTACT_811672] I/IIa 
trials evaluating pharmacokinetics, pharmacodynamics, safety/efficacy in adults with 
moderate to severe atpic dermatitis, adults with inadequately controlled severe 
asthma and adolescents with mild to moderate asthma.  
In summary, information is available for four of the completed and two of the 
ongoing trials. Based on data collected in these trials,  AMG [ADDRESS_1124003] recent version of 
MedImmune’s Investigator’s Brochure for AMG 157 (Version 3.0), a multiple dose 
study in subjects with mild atopic asthma (Study 20101183) demonstrated a decrease 
in blood and sputum eosinophils and a decrease in the Th2/Th1 balance based upon a 
new exploratory biomarker assay. Study [ADDRESS_1124004] on 
several lymphocyte subsets (CD3+, CD4+, CD8+ or CD19+), IgE scores, or plasma 
levels of CCL17, CCL22, or CCL27. 
1.[ADDRESS_1124005], TSLP-activated dendritic cells support the maintenance and further polarization 
of CRTH2+ Th 2 effector memory cells.27 Only dendritic cells (DCs) activated by 
[CONTACT_811673] a robust expansion of CRTH2+CD4+ Th [ADDRESS_1124006] indicated that TSLP might hinder the production and/or 
maintenance of Foxp3 + T-regulatory (Treg) cells in allergy. Specifically, in both 
mice and humans, low doses of TSLP have been shown to be capable of inhibiting 
Treg cell induction without significantly promoting Th 2 development, indicating that 
there is some degree of separation of these functions.28 These effects may be 
complex, however, as data from patients with Crohn’s disease have suggested that 
intestinal epi[INVESTIGATOR_811623].[ADDRESS_1124007] is predominant in humans. 
Given the generally pro-inflammatory and T regulatory-inhibitory effects of TSLP, 
inhibition of this cytokine as proposed in the current trial may lead to a reduction in 
Th 2 memory cells and increase in Treg cells and, when co-administered with 
allergen to allergic patients, may enhance or expedite the achievement of tolerance. 
1.5 TRIAL DESIGN 
 Overview 
The primary goal of this study is to determine whether the combination of anti-TSLP 
(AMG 157) plus antigen-specific immunotherapy will result in tolerance to the 
therapeutic antigen, as demonstrated by [CONTACT_811674] a therapeutic effect for a 
substantial period after stoppi[INVESTIGATOR_811624]. To address this we propose a 
randomized, placebo-controlled trial in which four groups of cat-allergic subjects are 
treated until week [ADDRESS_1124008] 14, 2017 
Anti-TSLP and cat immunotherapy 
 
 Why Total Nasal Symptom Score (TNSS) was Chosen as an Endpoint 
The use of total nasal symptom score (TNSS) relies on its relation to clinical 
symptoms and to experience gained in mechanistic analysis of nasal and other 
samples after in vivo challenge in the target organ for allergic rhinitis. TNSS is 
calculated with a scale of [ADDRESS_1124009] reported on a standardized approach to nasal challenge 
in which grass pollen-allergic individuals received increasing doses of grass pollen to 
determine the threshold dose that elicited a response. In subsequent challenges they 
received the same threshold dose that elicited a response and symptoms; tryptase and 
nasal cytokine levels were assessed over [ADDRESS_1124010] proceeding in a trial highly unlikely to reach its aims. 
 Why Cat Dander as an Allergen for Study 
There are several important clinical reasons justifying the choice to study cat allergic 
patients in this study:  1)  Cat-induced rhinitis and asthma occur commonly in the 
general population and represent a significant source of morbidity4;  2)  Clinical 
responses to cat allergen can be studied using reproducible methods, including nasal 
allergen challenge (NAC) and cat room challenge11; 3) Commercial cat dander 
extracts are well-standardized with respect to the allergenic potency.[ADDRESS_1124011] to measure T cell responses. Tetramers may 
be produced with principal epi[INVESTIGATOR_811625] a variety of HLA alleles, which can be used 
to study the evolution of antigen-specific reactions in individuals. 
 Mechanistic Questions: Overview 
The current trial allows for the exploration of mechanistic questions in several areas. 
The mechanisms of immunotherapy previously identified for other allergens 
including Th 1 deviation, production of blocking antibodies, and the generation of 
regulatory cells can be examined for cat immunotherapy. The study arm in which 
subjects receive both immunotherapy and anti-TSLP inhibition allows for the 
exploration of whether these same effects are magnified in extent or duration when 
TSLP signaling is impaired. It will be important to assess whether anti-TSLP alone 
has measurable mechanistic effects. These issues will be addressed in peripheral 
blood, skin, and nasal compartments. The mechanistic hypotheses and proposed 
techniques are laid out in more detail in Section 7. 
1.6 SUMMARY OF KNOWN AND POTENTIAL RISKS AND BENEFITS 
FOR HUMAN PARTICIPANTS  
 Study Medication Risks 
[IP_ADDRESS]  Allergenic Extract SQ (Standardized Cat Hair) 
Injection immunotherapy is commonly associated with local swelling at the allergen 
injection site, sometimes occurring within minutes but more typi[INVESTIGATOR_811626]. Large local cutaneous reactions may have associated pain and pruritus 
and occur in up to 10% of recipi[INVESTIGATOR_840]. Occasionally systemic allergic symptoms can 
occur, such as rhinitis, ocular symptoms, or urticaria. These symptoms can generally 
be managed with oral antihistamines. Rarely, anaphylaxis with wheezing and 
hypotension may occur. In this trial immunotherapy will be carried out in well-
equipped facilities by [CONTACT_811675]. Both local and systemic reactions are most common during 
the build-up phase of immunotherapy. 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124012] 14, 2017 
Anti-TSLP and cat immunotherapy 
 [IP_ADDRESS]  AMG [ADDRESS_1124013] been 
identified with AMG 157 administration. 
Important potential risks include Immune Complext Disease (Type III 
Hypersensitivity Reactions), Serious Infections, Parasitic Infestation/Infections , 
Hypersensitivity/Allergic Reactions and Infusion Reactions.  
Immune Complex Disease results from the formation of ADA, which can be a result 
of the administration of a mAb. No subjects received AMG 157 in the previous 
studies developed ADA.  
Due to the blockade of TSLP, AMG 157 has the potential to modulate systemic 
immune responses by [CONTACT_811676] 2-type T-cells. 
Therefore,there is a theoretical increased risk of serious infection,includingparasitic 
infections.In this trial participants will be screened and excluded for history of known 
immunosuppressive disorder, clinically significant infection and untreated systemic 
helminthic parasitic infection.  
As with any large molecule therapeutics, administration of AMG 157 may result in 
systemic and/or local reactions, as well as infusion-hypersensitivity reactions. To 
mitigate the risk of  severe hypersnsitivy and infusion reactions, subjects will be 
monitored for AEs and vital sign before, during and for 1 hour after the AMG 157 
administration. In addition, medical equipment  and study personnel trained to treat 
acute anaphylactic reactions will be immediately available.  
 Study Procedure Risks 
[IP_ADDRESS] Intradermal and Skin Prick Tests 
Participants may experience mild to moderate itchiness or local discomfort at the 
sites of intradermal injections and skin pricks with allergen and the positive control 
(histamine dihydrochloride 10 mg/mL). The symptoms are not bothersome and 
treatment with oral antihistamines is always available and is effective although 
almost never required. Systemic reactions including anaphylaxis after skin tests with 
standardized aeroallergen extracts are a theoretical risk but exceedingly rare. 
However, a physician is always present and drugs and equipment for treatment of 
anaphylactic reactions available. 
[IP_ADDRESS] Nasal Allergen Challenge (NAC) 
This trial will use nasal allergen challenge as one of several outcome measures. 
Challenge is expected to cause early (0-1 hr) and late (1-6 hr) allergic symptoms such 
as nasal congestion, sneezing, nasal discharge, and itchy, watery eyes. If nasal and/or 
ocular symptoms persist after the period of [ADDRESS_1124014] 14, 2017 
Anti-TSLP and cat immunotherapy 
 before and after nasal challenge and treatment with inhaled bronchodilators and 
corticosteroids will be immediately available. To minimize this risk, individuals with 
a pre-bronchodilator FEV1 of less than 80% of predicted are excluded from this trial. 
As for any intervention with allergen to which the patient is sensitive there is the 
theoretical risk of developi[INVESTIGATOR_457364]. Trained personnel, including 
a physician, as well as medications and equipment, will be immediately available to 
treat any reaction.  
[IP_ADDRESS] Nasal Lavage 
Prior to nasal challenge a saline nasal lavage with be performed with a commercially 
available preparation (SinuRinse®, NeilMed Pharmaceuticals) diluted in 240 mL (8 
oz) of warm distilled water. This is a non-irritant, preservative free, pH neutral 
solution that contains sodium chloride, sodium bicarbonate and iodine. SinuRinse® 
is widely available and no adverse effects are expected. 
[IP_ADDRESS]  Nasal Brushings 
Cells from the nasal epi[INVESTIGATOR_811627]. Risks include local burning with eye tearing, and rarely local 
bleeding. The symptoms are generally mild and resolve within minutes. 
[IP_ADDRESS] Venipuncture and Intravenous Access 
Participation in the trial requires blood drawing for laboratory assessment and 
intravenous access for drug administration. Potential risks are those associated with 
phlebotomy and include ecchymosis and infections at the site of needle puncture.  
 Potential Benefits 
Based on previous studies8 it is possible that participants who receive cat 
immunotherapy may have an improvement in symptoms. The impact of anti-TSLP, 
however, is unknown.  Some participants will not receive either cat immunotherapy 
or anti-TSLP. There is thus no assurance of therapeutic benefit from participation. 
[ADDRESS_1124015]. 
It is estimated that: 
 of those, 80% will meet the skin test eligibility criterion and undergo the 
nasal allergen challenge, 
 of those, 90% will meet the screening nasal allergen challenge eligibility 
criteria and undergo the remaining screening assessments; 
 of those, 90% will meet the remaining eligibility criteria and be enrolled; and  
 of those enrolled, 90% will successfully complete the baseline nasal allergen 
challenge and be randomly assigned. 
Thus it is estimated that about 205 individuals will need to be screened to meet the 
target randomization. 
Random assignment will be 1:1:1:1 to four groups: 
A) AMG 157 plus immunotherapy,  
B) placebo for AMG 157 plus immunotherapy, 
C) AMG 157 plus placebo for immunotherapy, or 
D) placebo for AMG [ADDRESS_1124016] 14, 2017 
Anti-TSLP and cat immunotherapy 
 widespread use in the clinical practice of allergy in the [LOCATION_002]. There will be 
an up-dosing period (approximately 12 weeks)  during which small doses are 
gradually increased to a maintenance dose. Dosing levels may be individually 
tailored based on subject response. The combined up-dosing and maintenance periods 
will total 48 weeks.  
Cat allergic subjects by [CONTACT_811677] 8Screen 
failure.
Stop
B
Cat immunotherapy .
Placebo .C
Placebo .
AMG 157 .A
Cat immunotherapy .
AMG 157 .TNSS 7 or less
D
Placebo .
Placebo .
week 0 to 11: Weekly cat immunotherapy or placebo updosing
Q4W AMG 157 IV (anti-TSLP) or placebo 
week 20 to 48:  Q4W cat immunotherapy or placebo maintenance
Q4W AMG 157 IV (anti-TSLP) or placebo
week 48 to 104: observation with nasal allergen challenges at weeks 52, 78, and 104
main comparisonB
Cat 
immunotherapy .
Placebo .C
Placebo .
AMG 157 .A
Cat immunotherapy .
AMG 157 .D
Placebo .
Placebo .week 11 to 14: Weekly cat immunotherapy or placebo maintenance
Week 14 to 20: Q2W cat IT or placebo maintenance
Q4W AMG 157 IV (anti-TSLP) or placebo 
 
Figure 1: Screening, allergen challenge, random assignment, treatment, and 
observation 
 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124017] of the trial will continue. Treatment of this cohort and 
of other enrolled participants will also continue. 
If there is strong evidence that the fully enrolled groups A and B will not show a 
significant decrease from baseline in TNSS compared to fully enrolled group D, the 
trial will be stopped. Otherwise, the trial will continue. This evaluation will be made 
based on an analysis described in Section 9.2.5 . 
3.2 STUDY DURATION 
Total study duration will be 154 weeks: 
 Study enrollment to occur over 46 weeks. 
 Individual subject study participation will be 108 weeks..  
3.3 STUDY ENDPOINTS 
 Primary Endpoint 
Total nasal symptom score (TNSS) AUC from 0 to 1 hour after cat allergen challenge 
at 104 weeks. TNSS is calculated with a scale of 0 to 3 on the 4 parameters of 
sneezing, rhinorrhea, nasal congestion and blockade, and pruritus. Maximum score is 
12. 
 Secondary Endpoints 
 
Other measures of allergic response including: 
 
1. Skin prick test endpoint titration at baseline, 1, 4, 12, 26, 52, 78, 104 weeks. 
2. Skin early phase response (EPR) to intradermal testing at baseline, 26, 52,104 
weeks. EPR is the skin response at 15 minutes. 
3. Skin late phase response (LPR) to intradermal testing at baseline, 26, 52, [ADDRESS_1124018] 14, 2017 
Anti-TSLP and cat immunotherapy 
 7. Peak nasal inspi[INVESTIGATOR_10229] (PNIF) LPR AUC at baseline, 26, 52, 104 weeks. 
LPR is the PNIF AUC from5 to 6 hours. 
8. PNIF EPR AUC at baseline, 26, 52, 78, 104 weeks. EPR is the PNIF AUC from 
0 to 1 hour. 
 Exploratory Endpoints 
Exploratory endpoints related to mechanisms of immune modulation and tolerance 
assessed prior to, during, and after therapy, including those related to: 
1. Local immune response in nasal fluid and/or cells for inflammatory cytokines 
and inflammatory mediators.  
2. Cells in peripheral blood will be collected for basophil activation at various time 
points during and after immunotherapy to measure basophil activation, cat 
antigen tetramers and cytokine profiles in response to in vitro cat antigen 
stimulation; cat antigen tetramers for changes during and after immunotherapy; 
and cytokine profiles after in vitro cat antigen stimulation. 
3. Serum components of cat-specific IgE; IgG and subclasses; and IgA inhibition of 
facilitated antigen presentation. 
3.[ADDRESS_1124019] (NIAID DSMB), which will review safety data and make 
recommendations regarding continuation, termination, or modification of the study. 
The DSMB will formally review the safety data six months after the first participant 
is randomized and then annually thereafter. The number of subjects who discontinue 
study treatment will be included in the reports prepared for the DSMB. 
In addition, safety data will be reviewed by [CONTACT_811678], ITN clinical trial physician, or 
protocol chair to warrant review, or when events occur that contribute to a stoppi[INVESTIGATOR_811628] 3.4.2 . 
 Stoppi[INVESTIGATOR_811629] 157 will be halted pending review by [CONTACT_32622], DAIT and the ITN if 
any of the following criteria are met: 
1. Death of any participant at least possibly related to study participation.  
2. Grade [ADDRESS_1124020] possibly related to study participation. 
3.5 DEFINITION OF HIGH AND LOW EXPOSURE TO CAT ALLERGEN 
Exposure to cats is assessed at screening. This assessment will determine whether a 
participant is stratified as described in section 6.2.1 to the high exposure or low 
exposure stratum. Exposure to cats is also assessed at intervals during participation. 
These assessments will allow tabulation of a participant’s exposure to cats during the 
trial. 
High exposure is defined as exposure to cats at least three times per week during each 
of the four weeks prior to the time of assessment. 
Low exposure is defined as not meeting the high exposure definition. In cases of 
uncertainty the clinical site investigator will determine high versus low exposure. 
[ADDRESS_1124021] meet all of the following criteria to be eligible for this study: 
1. Age 18-65 years. 
2. Removed in protocol version 4.0. 
3. History of moderate-severe allergic rhinitis (AR) caused by [CONTACT_811679] [ADDRESS_1124022].  
5. Removed in protocol version 3.0. 
6. Screening nasal allergen challenge in which: 
 TNSS is less than or equal to 3 after the 0 concentration (vehicle control 
only) dose,  
 TNSS increase is less than or equal to 1 from the TNSS prior to 
allergen administration to the TNSS after the 0 concentration (vehicle 
control only) dose, 
 TNSS is greater than or equal to [ADDRESS_1124023] dose, and 
 Between the first non-zero dose and [ADDRESS_1124024] dose, 
either:  
 3 or more sneezes are counted or   
 Greater than 20% drop in PNIF is recorded. 
7. Body mass index (BMI) is greater or equal to 18.0 and less than or equal to 
35.0  kg/m2, at screening. 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124025] 14, 2017 
Anti-TSLP and cat immunotherapy 
 8. Clinically acceptable physical examination and electrocardiogram (ECG) 
results (12-lead reporting RR, PR, QRS, QT and QTcF) prior to Day 0 based 
on the opi[INVESTIGATOR_871]. 
9. Adequate renal function defined as CrCl greater than 80 mL/min using the 
Cockcroft Gault equation. 
10. For women of childbearing age, a willingness to use a highly effective form of 
contraception for four months after last dose of study medication. Highly 
effective methods of birth control include abstinence, vasectomy by [CONTACT_811667], or a condom with spermicide in combination with either hormonal 
birth control, IUD or barrier methods used by [CONTACT_29619]. 
11. For men with female partners of childbearing potential, agreement not to 
donate sperm and to inform their female partner of their participation in this 
clinical study and use highly effective methods of birth control for four 
months after last dose of study medication. Highly effective methods of birth 
control include abstinence, vasectomy, or a condom with spermicide in 
combination with either hormonal birth control, IUD or barrier methods used 
by [CONTACT_29619]. 
12. The ability to give informed consent and comply with study procedures.  
13. Not currently taking and, for the duration of the study, agreement not to take 
any form of immunotherapy, including sublingual, subcutaneous or 
investigational immunotherapy. 
4.2 EXCLUSION CRITERIA 
Patients who meet any of the following criteria will not be eligible for this study: 
1. Removed in protocol version 4.0. 
2. Prebronchodilator FEV1 less than 80% of predicted value at screening visit. 
3. Removed in protocol version 3.0.   
4. History of asthma meeting the NAEPP EPR3 classification of mild-persistent 
or worse in the past year, other than with cat exposure, requiring regular 
inhaled corticosteroids for greater than 4 weeks per year. 
5. History of serious chronic medical conditions which might interfere with 
treatment or assessments. 
6. History of emergency visit or hospi[INVESTIGATOR_811630] 
12 months. 
7. History of chronic obstructive pulmonary disease (COPD). 
8. History of significant recurrent acute sinusitis, defined as [ADDRESS_1124026] resolved. 
13. High risk of parasitic disease as judged by [CONTACT_093]. 
14. Positive QuantiFERON® tuberculin test unless the potential subject has been 
treated with appropriate chemoprophylaxis.  
15. Exposure to an individual with active tuberculosis within six months from 
randomization. 
16. Subjects tested positive for HIV antibody, Hep B surface antigen, or Hep C 
antibody. 
17. Removed in protocol version 3.0. 
18. History of malignancy of any type, including basal cell and squamous cell 
cancers of the skin, within [ADDRESS_1124027] year or a history of greater than or equal to 10 
pack years. 
20. Previous immunotherapy treatment with cat allergen within the previous 
10 years. 
21. Any history of grade 4 anaphylaxis due to any cause as defined by [CONTACT_811680]. 
22. History of bleeding disorders or treatment with anticoagulation therapy. 
23. Treatment with omalizumab within 6 months prior to randomization. 
24. Currently taking any of the following medications:  beta blockers; tricyclic 
antidepressants; monoamine oxidase inhibitors; or anti-IgE monoclonal 
antibody treatment. 
25. Ongoing systemic immunosuppressive treatment. 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124028] with 
sensitivity of less than 50 mIU/mL within 72 hours before the start of study 
therapy. 
28. The use of any investigational drug or currently using an investigational device 
within 30 days or five half-lives (whichever is longer) prior to randomization. 
29. The presence of any medical condition that the investigator deems 
incompatible with participation in the trial. 
4.3 PREMATURE TERMINATION OF A PARTICIPANT FROM THE 
STUDY 
Withdrawal of consent. Participants who withdraw consent for further treatment or 
study procedures will be asked if they would be willing to complete an early 
termination visit ( Appendix 3 ). 
Investigator decision. The principal investigator [INVESTIGATOR_63803] a 
participant from the study for any reason.  
Failure to return. Participants who do not return for visits and who do not respond 
to repeated attempts by [CONTACT_811681]-up .  
Participants who terminate after randomization from the study will not be replaced.  
Participants who prematurely terminate due to withdrawal of consent for further 
treatment or investigator decision will be invited to complete study assessments at 
week 104 and any other preceding clinical allergy assessment visits including visits 
at weeks 26, 52, and 78 if applicable. However if they decline they will be asked to 
complete an early termination visit (Appendix 3) and will be discharged from the 
study. 
[ADDRESS_1124029] TSLP, expressed in a 
Chinese hamster ovary cell line. The molecule is a heterotetramer consisting of 2 
heavy chains of the IgG2 subclass and 2 light chains of the lambda subclass, which 
are covalently linked through disulfide bonds. 
AMG 157 (manufactured by [CONTACT_11337], Thousand Oaks, CA) is presented as a sterile, 
clear, and colorless to slightly yellow liquid for subcutaneous or intravenous 
administration. Each sterile vial is filled with 1 mL deliverable volume of 70 mg/mL 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124030] 14, 2017 
Anti-TSLP and cat immunotherapy 
 AMG 157 formulated with 10 mM sodium acetate, 9% (w/v) sucrose, 0.004% (w/v) 
polysorbate 20, pH 5.2. 
Placebo for AMG 157, maufactured by [CONTACT_11337], has the same formulation as ther 
drug product except there is no active AMG157. 
AMG [ADDRESS_1124031] to DAIT, NIAID. 
 Dosage, Preparation, and Administration 
AMG 157 at 700 mg or placebo of similar appearance will be administered by 
[CONTACT_811682]. Every 
four-week dosing has been previously tested and is based on information obtained in 
pharmacokinetic studies which demonstrate a prolonged (approximately 21 day) half-
life which supports dosing at this interval. The duration of AMG 157 specified in the 
current protocol has not been previously assessed.  
Both the drug and the placebo will be delivered by [CONTACT_811683] 100 ml of sterile 
diluent (5% dextrose) over a 1-hour period using a peristaltic pump. Participants will 
be observed in the clinic for [ADDRESS_1124032] should not be administered and if damage is observed, the study 
sponsor (DAIT NIAID) should be notified to obtain further instructions. 
The placebo for AMG [ADDRESS_1124033] as AMG 157. 
5.2 INVESTIGATIONAL MEDICATION – CAT IMMUNOTHERAPY AND 
PLACEBO 
 Formulation and Packaging  
Cat immunotherapy will comprise standardized cat allergen extract and is licensed in 
the US for allergen immunotherapy, and it is formulated as a long-acting suspension 
for subcutaneous injection. 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124034] will be obtained from ALK-Abelló, Inc. Port 
Washington, NY . 
The cat immunotherapy is 10,000 BAU/ml with inactive ingredients sodium c hloride 
(0.5%) sodium bicarbonate (0.25%) and glycerin 50 % (v/v). 
The placebo for immunotherapy will consist of the same inactive ingredients as the 
standardized cat allergen extract.  The placebo will be obtained from Allergy 
Laboratories, Inc., Oklahoma City, OK. 
Allergen and placebo are diluted in normal saline with phenol (0.4%) and 0.03% 
human serum albumin also obtained from Allergy Laboratories, Inc., Oklahoma City, 
OK. 
Cat immunotherapy/placebo will be packaged and distributed by a vendor under 
contract to DAIT, NIAID 
 Dosage, Preparation, and Administration 
Cat immunotherapy or placebo will be administered weekly during the updosing 
phase. The dosing schedule is shown in the table [ADDRESS_1124035] acting antihistamine (loratadine, or 
similar) at least 60 minutes but not more than 6 hours prior to each dose. Each dose 
should be administered as a subcutaneous injection with monitoring of peak 
expi[INVESTIGATOR_811631]. Participants will be 
observed in the clinic for 30 minutes prior to discharge. When two doses are 
administered in one visit, there should be a 30 minute interval between each 
injection. 
Additional details on formulation, dosage, preparation and administration can be 
found in the package insert available at: 
http://www.alk-
abello.com/US/products/productinformation/Lists/Package%20Inserts/Standardized%20Cat%
20Hair.pdf   
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124036] 14, 2017 
Anti-TSLP and cat immunotherapy 
  
 
Table 1:  Schedule of cluster immunotherapy injections 
Day Visit Volume (ml)  Vial # Fel d 1 
(BAU/ml) Feld1 
(BAU) Fel d 1 
(approx 
mcg) 
1 1 0.10 4 10 1 0.003 
  0.40 4 10 4 0.012 
8 2 0.10 3 100 10 0.03 
  0.20 3 100 20 0.06 
15 3 0.40 3 100 40 0.12 
  0.07 2 1000 70 0.21 
22 4 0.10 2 1000 100 0.3 
  0.15 2 1000 150 0.45 
29 6 0.25 2 1000 250 0.75 
  0.35 2 1000 350 1.05 
36 7 0.50 2 1000 500 1.5 
  0.07 1 10,000 700 2.1 
43 8 0.10 1 10,000 1000 3 
50 9 0.15 1 10,000 1500 5 
57 11 0.20 1 10,000 2000 6 
64 12 0.30 1 10,000 3000 9 
71 13 0.40 1 10,000 4000 12 
78 14 0.50 (end of 
updosing)  [ADDRESS_1124037] concentrate and all dilutions should be kept refrigerated at 2-8°C. Do not 
freeze, and do not open extract concentrate or placebo vials after the expi[INVESTIGATOR_811632].  The extract concentrate or placebo vial can be used for [ADDRESS_1124038] puncture. Sites will write on the vial the 13 week expi[INVESTIGATOR_811633]. 
5.3 DISCONTINUATION OF STUDY TREATMENT 
Study treatment, defined as the dosing and administration of study medication 
according to study specification, will be discontinued for an individual participant if 
any of the following criteria are met: 
 Two occurrences of grade 3 systemic reaction after administration of study 
therapy or nasal challenge. 
 An adverse event that, in the judgment of the principal investigator [INVESTIGATOR_811634], presents an unacceptable consequence or risk to the participant. 
 An illness or infection that is not associated with the condition under study and 
that requires treatment not consistent with protocol requirements; or, if a 
participant develops an intercurrent illness that in the judgment of the principal 
investigator [INVESTIGATOR_46011]. 
 Grade [ADDRESS_1124039] possibly related to study participation. 
 An inability or unwillingness to comply with the study protocol, and the protocol 
deviations are sufficient to jeopardize the participant’s well-being or the integrity 
of the study. 
 Pregnancy occurs during study participation. 
Participants who prematurely discontinue study treatment will be invited to complete 
study assessments at week 104 and any other proceeding clinical allergy assessment 
visits including visits at weeks 26, 52, and 78 if applicable. However if they decline 
they will be asked to complete the early termination visit ( Appendix 3 ). 
If study treatment is discontinued, the NIAID medical monitor should be notified. 
5.4 CONCOMITANT MEDICATIONS 
 Prophylactic and Emergency Rescue Medications 
Antihistamine (loratadine) will be provided and should be taken prior to each 
immunotherapy injection. 
Epi[INVESTIGATOR_294366]® (epi[INVESTIGATOR_238]) will be provided and participants will be instructed to bring 
the medication to each immunotherapy visit. A research staff member will verify that 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124040] 14, 2017 
Anti-TSLP and cat immunotherapy 
 the participant has the Epi[INVESTIGATOR_294366]® with them prior to each study treatment 
administration. 
 Contraception 
Low-dose estrogen containing oral contraception is permitted. 
 Prohibited Medications 
Use of the medications listed in the exclusion criteria in Section 4.2  is prohibited 
during study participation. 
5.5 DRUG ACCOUNTABILITY 
Under federal regulations (21CFR 312.62) an investigator is required to maintain 
adequate records of the disposition of the investigational product, including the date 
and quantity of drug that was received, the participants to whom drug was dispensed 
(participant by [CONTACT_80934]), and an account of any drug accidentally or 
deliberately destroyed. The investigator will ensure that the investigational product 
supplies are stored as specified in the protocol and pharmacy manual in a secured 
area, with access limited to authorized study personnel as described in the clinical 
study agreement. 
Records for receipt, storage, use, and disposition of the study drug will be maintained 
by [CONTACT_80935]. A drug-dispensing log will be kept current for each participant and 
will contain the identification of each participant and the date and quantity of drug 
dispensed. All remaining unused investigational product will be returned to the 
sponsor or sponsor’s representative after study termination, or destroyed with the 
permission of the sponsor in accordance with applicable law and study site 
procedures. If investigational product is to be destroyed locally, the investigator will 
provide documentation in accordance with sponsor’s specifications. 
All records regarding disposition of the investigational product will be available for 
inspection by [CONTACT_93243]. 
5.[ADDRESS_1124041] occur 
within the time limits specified below: 
Visit -2:   no window 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124042] 14, 2017 
Anti-TSLP and cat immunotherapy 
 Visit -1:   +14 days 
Visit 0:   +7 days 
Visits 1 through 25:  ±3days  
Visits 26 – 31:   AMG 157/placebo and cat immunotherapy/placebo may be 
given on separate days, ±3 days 
Visit 32: ±7 days 
Visits 33 through 39:  ±[ADDRESS_1124043]-protected, web-based, randomization system (RhoRAND™) 
maintained by [CONTACT_63662] (SDCC). 
Random assignment will be stratified by [CONTACT_811684] 3.5 , and by [CONTACT_811685]. 
 Blinding 
Blinding will be maintained for all study participants and trial personnel after 
randomization, with the exception of the site’s pharmacy staff and unblinded 
qualified individual to administer cat immunotherapy or placebo.  This  unblinded 
qualified individual may also infuse the AMG 157 or placebo but will not be 
involved in performing any study assessments . 
 Unblinding 
Unblinding before the study is completed will occur only if a participant’s well-being 
is threatened and the investigator believes unblinding is necessary to protect the 
participant.  
Before treatment assignment for an individual participant is unblinded, the 
principal/site investigator must confer with the NIAID medical monitor. The site 
investigator will notify the protocol chair of the unblinding event, and the medical 
monitor will notify the study management team (SMT).  
The emergency unblinding will be recorded and reported to the DSMB. A full 
account of the event will be recorded, including the date and time of the emergency, 
the reason for the decision to unblind, and the names of the medical monitor and 
others who were notified of the emergency. During site visits, the site monitor must 
verify that the medical monitor was notified and that a written account was 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124044] 14, 2017 
Anti-TSLP and cat immunotherapy 
 completed. The reasons for unblinding of a participant’s treatment will be included in 
the final study report. ITN and NIAID approval is required for unblinding the 
treatment of an individual participant or subgroups of participants for unplanned 
interim analyses to support DSMB reviews and final analysis.  
An exception to the above rule is that IND Safety Reports that will be reported to the 
FDA, DSMB, and IRBs in an unblinded fashion as requested by [CONTACT_811686]. 
6.3 GENERAL ASSESSMENTS 
 Medical history 
 Allergy history 
 Comprehensive physical examination (includes height and weight) 
 Limited physical examination 
 Vital signs: blood pressure, temperature, pulse, and respi[INVESTIGATOR_697] 
 Pulmonary function testing (spi[INVESTIGATOR_038]) 
 Pre and post peak flow testing 
 Adverse events 
 Concomitant medications 
6.[ADDRESS_1124045] 14, 2017 
Anti-TSLP and cat immunotherapy 
 Table 2: Medication washout periods 
Medication  Time 
Inhaled β-agonists  
Short acting (e.g., Albuterol)  6 hours 
Long acting (e.g., Salmeterol, Serevent, Formoterol, Foradil, Oxis)  2 days 
Oral β-agonists  
Conventional release (e.g., Albuterol, Ventolin)  12 hours 
Extended  release (e.g., albuterol-ER) 2 days    
Romolyn drugs  (e.g., Intal  nebulizer solution ) 7 days 
Leukotriene modifiers, short-acting  (e.g., zafirlukast, Accolate)  3 days 
Leukotriene modifiers, long-acting  (e.g., montelukast , Singulair ) 7 days 
Inhaled corticosteroids  (e.g., beclomethasone,   Qvar, Budesonide, Pulmicort, Symbicort, 
mometasone,  Asmanex , Dulera, fluticasone, Flovent, Advair )  14 days 
Oral steroid  (e.g., prednisone, prenisolone)  [ADDRESS_1124046] 14 days 
Short-acting preparation (e.g., theophylline , Aminophylline)  3 days 
Long-acting preparation (e.g.,  Slo-bid, Theodur ) 7 days 
Rhinitis Medications  Time 
Cromolyn sodium  (e.g.,  Nasalcrom ) 7 days 
Oral Antihistamines  (e.g., Cetirizine, Desloratadine, Claritin, Fexofenadine, Allegra, 
Levocetirizine, Xyzal. Loratadine, Chlorphenamine, Bendryl, Atarax)  5 days 
Topi[INVESTIGATOR_811635] (e.g. azelastine, Astelin) 5 days 
Decongestants ( e.g., pseudoephedrine, phenylephrine)  3 days 
Antihistamine-decongestant tablets/liquids  (e.g., Zyrtec D, Claritin -D)   5 days 
Nasal corticosteroids  (e.g., Flonase, Nasonex, Nasacort, Fluticasone Propi[INVESTIGATOR_16847], Qnasl, 
Beclomethasone, flunisolide,  Budesonide, Rhinocort Aqua, Dymista)  14 days 
Topi[INVESTIGATOR_811636] (e.g. Atrovent, ipratropi[INVESTIGATOR_1890]) 3 days 
Anticoagulants and Anti-platelet agents  Time 
Low-dose aspi[INVESTIGATOR_248], NSAIDs, other anti -platelet agents  2 days 
 
 Nasal Allergen Challenges 
The screening nasal allergen challenge is carried out as a graded, up-dosing allergen 
exposure starting with the vehicle control only (16.7% glycerin and normal saline) 
dose and then with the same, commercially available, standardized cat allergen 
extract used for immunotherapy as described in an accompanying standard operating 
procedure. A procedure similar to that reported by [CONTACT_811687]. (2012) will be 
used. Subjects who meet protocol inclusion criteria with respect skin testing may 
undergo the nasal allergen challenge at screening visit, baseline visit and subsequent 
challenge visits(See Section 4.). Assessments performed during the challenges 
include peak expi[INVESTIGATOR_10229], forced expi[INVESTIGATOR_3741] [ADDRESS_1124047] 
with a similar Fel d 1 microgram/mL levels.  The choice of a replacement lot will be 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124048] be 
within +/- 26% of the lot being substituted. 
When a lot change  is  anticipated due to the expi[INVESTIGATOR_811637] [ADDRESS_1124049] used for the nasal allergen challenges may be the same 
as, or different than, the lot used for immunotherapy in any one participant. 
 Skin Testing 
[IP_ADDRESS] Overview 
All skin test procedures are consistent with current clinical practice and product 
labeling. All cat allergen extracts will be purchased from ALK-Abelló and packaging 
and delivery of these materials will be done by a designated drug distributor under 
contract to NIAID. Skin testing should be done with the same lot of cat allergen 
extract that is used for nasal allergen assessments in an individual participant. 
Washout periods for specific medications prior to skin testing are listed in the table. 
[IP_ADDRESS] Skin Prick Test for Cat Allergen 
Skin prick test (SPT) for cat allergen will be done as indicated in the SOE.  
Controls include:  negative control (50% glycerin), and positive control (10 mg/mL 
histamine dihydrochloride). Subjects will be assessed 15 (+2) minutes after 
application. 
[IP_ADDRESS] Intradermal Skin Test for Early and Late Phase Responses: 
Cat Allergen Extract 
Intradermal skin testing with cat allergen extract will be done at times indicated in 
the SOE. 
For this test, concentrations of standardized cat hair extract specified in an SOP will 
be applied intradermally to the forearm. Subjects will be assessed 15 (+2) minutes 
and 6 hours (± 15 minutes) after application.  
[IP_ADDRESS] Skin Prick Test (SPT) Serial Titration: Cat Allergen Extract 
Skin prick test titration with cat allergen extract will be done at times indicated in the 
SOE. 
A dilution series of standardized cat allergen extracts will be prepared. Each dilution 
will be applied and punctured in duplicate. Subjects will be assessed 15 (+2) minutes 
after application.  
6.5 CLINICAL LABORATORY ASSESSMENTS 
 Serum pregnancy test 
 Urine pregnancy test 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124050] 14, 2017 
Anti-TSLP and cat immunotherapy 
  Hematology: Complete blood count with differential 
 Comprehensive chemistry:  Albumin, bilirubin total, creatinine, glucose, 
potassium, protein total, sodium, alamine amino transferase (ALT) (SPGT), 
aspartate amine transferase (AST) (SGOT), and urea nitrogen (BUN) 
 QuantiFERON® TB test 
 HIV Antibody  
 Hepatitis B surface antigen test 
 Hepatitis C antibody test 
 Creatinine Clearance 
6.6 PHARMACOKINETIC AND AMG 157 NEUTRALIZING ANTIBODY 
TESTING 
Serum samples to assess pharmacokinetic and AMG 157 serum antibody levels will 
be collected at drug trough from all participants at the times indicated in the schedule 
of events.  
7 T OLERANCE ASSAYS 
7.1 RATIONALE FOR IMMUNE STUDIES 
Thymic stromal lymphopoietin (TSLP), a member of the IL-[ADDRESS_1124051] many different cell types including: 
dendritic cells (DCs), basophils, eosinophils, mast cells, T cells, B cells, and 
epi[INVESTIGATOR_1663].[ADDRESS_1124052] been described for grass immunotherapy. These 
may include stimulation of Th 1-type helper lymphocytes, decrease in Th 2 cells and 
induction of T regulatory (Treg) cells that produce IL-10 and TGF- .12,[ADDRESS_1124053] cells, eosinophils and basophils. As noted in the 
introduction, less is known about the corresponding mechanisms after cat 
immunotherapy. Ewbank et al. and Nanda et al. both reported approximately two to 
three-fold increases in cat-specific IgG4 after as little as 5 weeks of subcutaneous 
immunotherapy.10,11 In one report there was a reported decrease in CD4/IL-4-positive 
(Th 2-like) cells10 but this was not a consistent finding.[ADDRESS_1124054] cells. We hypothesize that 
TSLP blockade by [CONTACT_14181]-TSLP will inhibit Th 2 responses and thus combine with 
immunotherapy to lead to a long-lasting desensitization to cat allergens and 
potentially to tolerance of these allergens. 
Mechanistically tolerance could occur through multiple routes and the experiments 
summarized below are designed to address these questions. Note that the primary 
goal of this study is to determine whether the combination of anti-TSLP (AMG 157) 
plus antigen-specific immunotherapy will result in tolerance to the therapeutic 
antigen that persists for a substantial period after stoppi[INVESTIGATOR_811624]. 
Previous studies of the mechanism of subcutaneous immunotherapy, including those 
performed by [CONTACT_489143], have highlighted the value of studying immune and 
inflammatory responses in the target organ rather than just in the peripheral blood. 
Therefore, this study will compare changes in the nasal mucosa/secretions with 
systemic changes in T-cell and humoral responses and the clinical response to nasal 
allergen provocation before, during and at intervals after immunotherapy and TSLP 
blockade. 
7.2 HYPOTHESES TO BE TESTED 
Subcutaneous immunotherapy with cat allergens induces desensitization to cat 
allergens of unknown durability. We hypothesize that adding anti-TSLP to cat 
immunotherapy will increase the duration of desensitization and potentially induce 
tolerance to cat antigens by [CONTACT_811688]:  
1. Long-lived suppression of allergen-induced early and late phase responses for at 
least 52 weeks after discontinuation of immunotherapy. 
2. Change in the T effector/T regulatory cell balance. We predict that either 
antigen-specific T effector cells will decrease and/or T regulatory cells will 
increase. 
3. Immune deviation in favor of Th 1 responses and relative suppression of local Th 
2-mediated allergic inflammation in the nasal mucosa. 
4. “Protective” inhibitory antibody responses that persist for at least 56 weeks after 
discontinuation and are surrogate and/or predictive of the clinical response to 
immunotherapy. 
In order to test these hypotheses, we shall perform intradermal skin provocation 
testing with measurement of immediate and late skin responses before and at 
intervals after immunotherapy. Early skin responses occur in minutes and represent 
IgE-driven mast cell activation and degranulation. Late responses occur several hours 
later and are mediated by T cells, eosinophils, and basophils. At corresponding time 
points we will perform nasal allergen challenge with measurement of early and late-
phase nasal symptoms, along with nasal fluid, nasal epi[INVESTIGATOR_811638], and 
peripheral blood sampling. The hypotheses described above will be tested using a 
variety of  assays, examples of which are described in the sections below. 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124055] fails to occur, it may be decided that there is 
minimal value in performing certain mechanistic assays. 
7.4 LOCAL IMMUNE RESPONSES IN NASAL MUCOSA 
Nasal allergen challenge will be performed at baseline and at 26, 52, and 104 weeks. 
Along with clinical signs and symptoms score, nasal secretions will be collected at 
multiple time points at baseline, and at 26, 52, and 104 weeks. These analyses are 
based on pi[INVESTIGATOR_811639]. Scadding, Durham et al . in collaboration with 
the ITN, to support the GRASS study (ClinicalTrials.gov Identifier: NCT0335139). 
Note, that as shown in Figure [ADDRESS_1124056]-challenge. 
 
Figure 2: Th [ADDRESS_1124057]-lavage
+00:05
+00:15
+00:30
+01:00
+02:00
+03:00
+04:00
+05:00
+06:00020406080100 pg/ml*
***
*n=[ADDRESS_1124058]-lavage
+00:05
+00:15
+00:30
+01:00
+02:00
+03:00
+04:00
+05:00
+06:000500100015002000 pg/ml*
***
*n=[ADDRESS_1124059] 14, 2017 
Anti-TSLP and cat immunotherapy 
  
Epi[INVESTIGATOR_811640]/scrapi[INVESTIGATOR_811641]. However, brushings will only be taken 6 hours after the 
challenge to avoid inflammatory sampling effects on nasal secretions taken at earlier 
time-points.  
Nasal secretions will be assayed for inflammatory mediators, including TSLP, and 
local antibodies. RNA will be extracted from the epi[INVESTIGATOR_811642], such as RT-PCR or RNAseq, for 
comparison between the four treatment groups. 
 Nasal fluid will be obtained before and at intervals up to 6 hours after nasal 
allergen challenge for measurement of cytokines, such as IL-5, IL-13, IF - , IL-10, 
TGF-, antibodies (IgE, IgG4 and IgA2 using CAPRAST) and inflammatory 
mediators such as ECP (eosinophilic cationic protein), tryptase, basogranulin, and 
TSLP. 
 Nasal epi[INVESTIGATOR_811643] (2 or 3 mm). The brush 
will be introduced into a microcentrifuge tube, covered with 1.5 mL extraction 
buffer RLT (Qiagen), and stored in this buffer at －80 °C for up to [ADDRESS_1124060] by [CONTACT_937]-PCR. These may 
include genes for:  
 epi[INVESTIGATOR_1231]-derived chemokines such as TSLP, MDC, TARC, Eotaxin, 
RANTES 
 adhesion molecules such as ICAM-1 
 cytokines such as IL-8, GM-CSF and those that may possibly be detected in trans-
epi[INVESTIGATOR_811644], including IL-4, IL-5, IL-9, IL-13, Interferon-
gamma, IL-[ADDRESS_1124061]-lavage
+00:05
+00:15
+00:30
+01:00
+02:00
+03:00
+04:00
+05:00
+06:00050100150200 pg/ml*
*IL-13
**
*
*
*n=[ADDRESS_1124062] 14, 2017 
Anti-TSLP and cat immunotherapy 
  newer cytokines of potential interest e.g., IL-25, IL-22, IL-33 and IL-35 
 transcription factors of interest e.g., GATA-3, STAT-6, T Bet and FOXP3  
7.[ADDRESS_1124063]. Ziegler conducted analyses of single nucleotide polymorphisms (SNPs) 
of the TSLP gene in human bronchial epi[INVESTIGATOR_1663], to determine if there are 
functional genetic variants of TSLP that contribute to disease.[ADDRESS_1124064] been identified: 
the long form, which is associated with allergic inflammation, was highly induced by 
[CONTACT_52362] (I:C) (double-stranded RNA) stimulation in normal human bronchial epi[INVESTIGATOR_15129] (NHBE) ( P = 0.0060). The SNP rs3806933 (−847C > T) in the promoter region 
of long-form TSLP was found to create a binding site for the transcription factor 
activating protein (AP)-1, and in vitro functional analyses demonstrated that the SNP 
enhanced AP-1 binding to the regulatory element. The functional variant increased 
promoter-reporter activity of long-form TSLP in response to poly (I:C) stimulation in 
NHBE. Functional genetic polymorphism of the TSLP gene thus appears to have the 
potential to contribute to Th 2-polarized immunity through higher TSLP production 
by [CONTACT_811689][INVESTIGATOR_811645].[ADDRESS_1124065] 14, 2017 
Anti-TSLP and cat immunotherapy 
 (SOPs) for PBMC separation, and freezing. This will ensure that standardized 
procedures are used and that high quality material is obtained for testing. PBMCs 
will be stored in the vapor phase of liquid nitrogen until use. 
7.6.2 Cellular Assays 
To address the functional status of T cell responses, various cell-based assays using 
previously frozen PBMCs can be used to estimate the frequency, phenotype, cytokine 
and transcriptional profiles of allergen-specific T cells. 
Allergen specific CD4 T cells are present at very low frequencies in peripheral blood 
and differ in function/frequency in allergic vs. non-allergic individuals. MHC (major 
histocompatibility complex) class II “tetramers”, a fluorescently tagged multivalent 
synthetic mimic of the peptide binding proteins found on the surface of antigen 
presenting cells can be used to directly identify and enumerate cat allergen Fel d1 
epi[INVESTIGATOR_811646]4 T cells using flow cytometry. Additional steps may be 
performed to determine the effector function of antigen-specific CD4 T cells.  For 
example, intracellular cytokine staining for IL-4, IL-5, IL-9, IL-13, IFNg, IL-17, 
IL10, Foxp3 and TGF  could be performed to assess frequencies and ratios of Th1, 
Th2, Th9, Th17, Th17.1, and Treg cells.  Alternatively, antigen-specific CD4 T cells 
could be FACS sorted for transcriptional analysis by [CONTACT_811690]. 
The ability to use these reagents will depend on the overlap between HLA alleles 
among study participants and available reagents.  
Since tetramers are not currently available for all haplotypes other T-cell assays may 
also be performed.  We plan to pi[INVESTIGATOR_2268] a CD154 up-regulation assay for monitoring cat 
allergen-reactive CD4 T cells with Bill Kwok at BRI using PBMC isolated from ~70 
mL fresh blood collected from 15 study participants at the Asmthma Inc Site.  This 
assay requires overnight in vitro stimulation of ~40 million PBMCs with Fel d 1 and 
Feld 4 peptides/cat allergen extract in the presence of anti-human CD40 blocking 
mAb.  ½ of the cells will be collected and analyzed by [CONTACT_4133], and the other 
half will be used for sorting CD154+ and CD154- CD4 T cells for RNAseq analysis.  
Since additional PBMCs from these same study participants/visits will be processed 
and cryopreserved by [CONTACT_811691], we will be able to 
directly compare the performance and utility of the CD154 up-regulation assay for 
cryopreserved PBMCs tested in a single batch compared to fresh PBMC tested in 
real-time.  If the CD154 upregulation assay can be validated on cryopreserved 
PBMCs, this assay would be an attractive option for determining the impact and 
durability of treatment on frequencies and phenotypes of cat allergen specific CD4 T 
cells in all study participants. 
 For optimum use, these assays require [ADDRESS_1124066] 14, 2017 
Anti-TSLP and cat immunotherapy 
 determined by [CONTACT_80954]. This assay has the advantage that it can be reliably 
performed with only two million previously frozen, viable PBMCs.  
Treatment with anti-TSLP may lead to decreased STAT 5/[ADDRESS_1124067] that changes in the surface expression of Fc RI may enhance 
local inflammation after cell recruitment to the site of allergen challenge. Up-
regulation of Fc RI is known to amplify the capacity for uptake and presentation of 
allergen to Th 2 effector cells via IgE mediated allergen capture and secondarily 
programming of IL-4/IL-13 dependent activated macrophages. Therefore, we may 
measure surface expression of Fc RI on plasmacytoid and myeloid dendritic cells as 
well as monocytes by [CONTACT_811692]. 
7.7 SERUM ASSAYS 
Serum antibody responses will be measured to determine levels of total and 
allergen-specific antibodies. These measurements will include testing for total IgE 
and IgG and allergen-specific IgE, IgG1, IgG4, and IgA2, and will be performed in 
the ITN core. A role for IgG1, IgG4, and IgA2 in blocking allergen-specific 
reactivity is postulated; however, previous studies showed various results in allergen-
specific antibody induction after immunotherapy. 
In addition to antibody testing, serum samples may be used in functional assays 
including measurement of IgG-associated serum inhibitory activity of IgE-facilitated 
binding of allergen-IgE complexes to B cells (IgE-FAB (facilitated antigen binding), 
a surrogate measure of IgE-FAP (facilitated antigen presentation) and serum 
inhibitory activity for basophil histamine release (BHR). These two assays address 
the degree of blocking of binding of allergen-IgE complexes to low- and high affinity 
IgE receptors (respectively). Serum from treatment and placebo groups will be 
assessed for its inhibitory activity for IgE-FAB. The time course and magnitude of 
changes in inhibitory activity for IgE-FAB will be compared with clinical symptoms, 
clinical scores, and allergen-specific IgE, IgG1, IgG4, and IgA2 levels. Similarly, 
serum will be screened for its inhibitory activity in BHR assays. 
8 A DVERSE EVENTS 
8.1 OVERVIEW 
The investigator is responsible for the detection and documentation of events meeting 
the criteria and definition of an AE (adverse event) or SAE (serious adverse event) as 
described in Section 8.2.[ADDRESS_1124068] 14, 2017 
Anti-TSLP and cat immunotherapy 
 be recorded in the source documents and on the appropriate electronic CRF(s). All 
data will be reviewed periodically by [CONTACT_4318], which may provide 
recommendations to NIAID about withdrawing any participant and/or terminating the 
study because of safety concerns.  
Adverse events that are classified as serious according to the definition of health 
authorities must be reported promptly and appropriately to the NIAID, ITN, principal 
investigators in the trial, IRBs, and health authorities. This section defines the types 
of AEs and outlines the procedures for appropriately collecting, grading, recording, 
and reporting them. Information in this section complies with 21CFR 312; ICH 
Guideline E2A : Clinical Safety Data Management: Definitions and Standards for 
Expedited Reporting ; and ICH Guideline E-6: Guidelines for Good Clinical Practice ; 
and applies the following standards: 
 Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent 
Volunteers Enrolled in Preventive Vaccine Clinical Trials (published September 
2007) for local reactions to immunotherapy and study procedures. 
 WAO Subcutaneous Immunotherapy Systemic Reaction Grading System for 
systemic reactions to immunotherapy and study procedures. 
 National Cancer Institute (NCI) Common Terminology Criteria for Adverse 
Events Version 4.03  (published June 14, 2010) for all other reactions to 
immunotherapy and study procedures. (This document is referred to herein as the 
“NCI-CTCAE manual.”)  
8.2 DEFINITIONS 
 Adverse Event 
An adverse event (AE) is any occurrence or worsening of an undesirable or 
unintended sign, symptom, laboratory finding, or disease that occurs during 
participation in the trial. An AE will be followed until it resolves or until [ADDRESS_1124069] 14, 2017 
Anti-TSLP and cat immunotherapy 
 Common local symptoms due to immunotherapy, skin testing and nasal allergen 
challenge will be graded according to table 3 below. Only those reactions assessed as 
grade 2 or greater will be reported as adverse events. Please refer to Section 8.4.1 for 
specifications of local reactions related to nasal allergen challenge.  
Table 3: Grading of local reactions to cat immunotherapy and to study 
procedures 
(Adapted from Guidance for Industry: Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (published 
September 2007). 
Grade 1 2 3 4 
Cat immunotherapy and skin testing  
Pruritis Interfering with 
the usual daily 
activities or sleep, 
but requiring no 
medication other 
than topi[INVESTIGATOR_030], or 
antihistamines.  Interfering with 
the usual daily 
activities or sleep 
and requiring 
oral steroids. Requiring  a visit 
to a health care 
provider  for 
treatment Not applicable 
Pain Does not interfere 
with activity Repeated use of 
non-narcotic 
pain reliever > 
24 hours or 
interferes with 
activity Any use of 
narcotic pain 
reliever or 
prevents daily 
activity Emergency room 
(ER) visit or 
hospi[INVESTIGATOR_811647]/ 
Redness* 2.5 – 5 cm > 5 cm and 
interferes with 
activity >10 cm or 
prevents daily 
activity Necrosis or 
exfoliative 
dermatitis 
Induration/ 
Swelling** 2.5 – 5 cm and 
does not interfere 
with activity > 5 cm and 
interferes with 
activity >10 cm or 
prevents daily 
activity Necrosis 
Nasal allergen challenge  
 Requiring 
antihistamines, 
decongestants or 
nasal steroids as 
rescue medication Requiring oral 
steroids as rescue 
medication   Requiring a visit 
to a health care 
provider for 
treatment. Life threatening 
and/or requiring 
hospi[INVESTIGATOR_059] 
(local upper 
airway 
obstruction)  
*  In addition to grading the measured local reaction at the greatest single diameter, the measurement 
should be recorded as a continuous variable. 
**  Induration/Swelling should be evaluated and graded using the functional scale as well as the actual 
measurement. 
 Suspected Adverse Reaction and Adverse Reaction  
Suspected adverse reaction (SAR) means any adverse event for which there is a 
reasonable possibility that the study drug caused the adverse event. For the purposes 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124070] 14, 2017 
Anti-TSLP and cat immunotherapy 
 of safety reporting, ‘reasonable possibility’ means there is evidence to suggest a 
causal relationship between the drug and the adverse reaction. A suspected adverse 
reaction implies a lesser degree of certainty about causality than adverse reaction, 
which means any adverse event caused by a drug (21 CFR 312.32(a)).   
An adverse reaction (AR) means any adverse event caused by a study drug. Adverse 
reactions are a subset of all suspected adverse reaction for which there is reason to 
conclude that the drug caused the event. 
 Serious Adverse Event  
An AE or SAR is considered “serious” if, in the view of either the investigator or 
DAIT/NIAID it results in any of the following outcomes (21 CFR 312.32(a)): 
 Death:  A death that occurs during the study or that comes to the attention of the 
investigator during the protocol-defined follow-up period must be reported 
whether it is considered treatment related or not. 
 A life-threatening event: An AE or SAR is considered “life-threatening” if, in the 
view of either the investigator or the medical monitor, its occurrence places the 
subject at immediate risk of death. It does not include an AE or SAR that, had it 
occurred in a more severe form, might have caused death.  
 Inpatient hospi[INVESTIGATOR_1081]. 
 Persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions. 
 An event that requires intervention to prevent permanent impairment or damage. 
An important medical event that may not result in death, be life threatening, or 
require hospi[INVESTIGATOR_12475], based on appropriate 
medical judgment, it may jeopardize the participant and may require medical or 
surgical intervention to prevent one of the outcomes listed above. 
 Congenital anomaly or birth defect. 
 ‘Expected’ versus ‘Unexpected’ Suspected Adverse Reaction 
A suspected adverse reaction is considered “expected” when it is listed in the 
investigator brochure, the package insert or the protocol. A suspected adverse 
reaction is considered “unexpected” when its nature (specificity), severity, or rate of 
occurrence is not consistent with applicable product information as described in the 
safety information provided in the investigator brochure, the package insert or the 
protocol (21 CFR 312.32(a)). A serious unexpected suspected adverse reaction is 
referred to as a S[LOCATION_003]R. 
For this study, expectedness will be determined by [CONTACT_811693]’s brochure for AMG 
157. Expectedness for study procedures (nasal allergen challenge, intradermal skin 
test and skin prick test) will be determined by [CONTACT_811694].  
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124071] 14, 2017 
Anti-TSLP and cat immunotherapy 
 8.3 COLLECTING AND RECORDING ADVERSE EVENTS 
 Methods of Collection 
Adverse events may be collected as follows: 
 Observing the participant. 
 Questioning the participant in an objective manner. 
 Receiving an unsolicited complaint from the participant. 
An abnormal value or result from a clinical or laboratory evaluation (e.g., a 
radiograph, an ultrasound, or an electrocardiogram) can also indicate an AE if it is 
either determined by [CONTACT_811695] a grade [ADDRESS_1124072] be recorded 
in the source document and as an AE on the appropriate AE form(s). The evaluation 
that produced the value or result should be repeated until that value or result returns 
to normal or can be explained and the participant’s safety is not at risk. 
8.3.2  Collection Period for Adverse Events and Serious Adverse 
Events 
[IP_ADDRESS] Adverse Events 
All systemic reactions and all grade 2 or greater local reactions occurring within 72 
hours after cat immunotherapy and/or study procedures (see Section 8.2.2 ) will be 
collected from visit -2 (week -4) until the participant completes the study (visit 
40/week 104) or prematurely withdraws from the study. All other AEs will be 
collected from visit 0 (week 0) until the participant completes the study (visit 
40/week 104) or prematurely withdraws from the study. 
[IP_ADDRESS] Serious Adverse Events 
Serious AEs will be collected from visit -2 (week -4) until 30 days after the 
participant completes the study (visit 40/week 104) or prematurely withdraws from 
the study. 
8.3.[ADDRESS_1124073] all AEs on the appropriate eCRF. 
The investigator will treat participants experiencing AEs appropriately and observe 
them at suitable intervals until their symptoms resolve or their status stabilizes. 
[IP_ADDRESS] Recording SAEs 
Serious AEs will be recorded on the SAE eCRF and health authorities will be 
notified as outlined in Section 8.5.2.  
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124074] 14, 2017 
Anti-TSLP and cat immunotherapy 
 8.4 GRADING AND ATTRIBUTION OF ADVERSE EVENTS 
8.4.1 Grading Criteria 
[IP_ADDRESS] Adverse Events Related to Cat Immunotherapy or to AMG 157 
Immunotherapy 
Local reactions to cat immunotherapy not associated with systemic signs or 
symptoms will be graded according to the table in Section 8.2.2 .  
Systemic reactions to cat immunotherapy will be graded according to the WAO 
Subcutaneous Immunotherapy Systemic Reaction Grading System (see appendix 4).  
All other adverse events related to cat immunotherapy will be graded according to the 
criteria set forth in the NCI-CTCAE (v4.03 published June 14, 2010). 
AMG 157 
All adverse reactions related to AMG 157 will be graded according to the NCI-
CTCAE v4.03, published June 14, 2010. 
[IP_ADDRESS] Adverse Events Related to Nasal Allergen Challenge and Skin 
Testing 
Local reactions related to nasal allergen challenge and skin testing not associated 
with systemic signs or symptoms will be graded according to the table in Section 
8.2.2. Only grade 2 or greater local reactions will be recorded as AEs. Systemic 
reactions related to skin testing or to nasal allergen challenge procedure will be 
graded according to the WAO Subcutaneous Immunotherapy Systemic Reaction 
Grading System (see Appendix 4 ). All grades of system reactions should be recorded 
as AEs and as SAEs if serious criteria are met.  
The following specifications considered local, not systemic reactions will apply for 
nasal allergen challenges:  
 rhinitis (e.g., sneezing, rhinorrhea, nasal pruritus and/or nasal congestion) and  
 cough perceived to originate in the upper airway, not the lung, larynx, or trachea 
All other adverse events related to study procedures will be graded according to the 
criteria set forth in the National Cancer Institute’s Common Terminology Criteria for 
Adverse Events, Version 4.03  (published June 14, 2010). 
[IP_ADDRESS] All Other Adverse Events 
All other adverse events will be graded on a scale from 1 to 5 according to the 
following standards in the NCI-CTCAE manual: 
 Grade 1 = mild adverse event 
 Grade 2 = moderate adverse event 
 Grade 3 = severe and undesirable adverse event 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124075] 14, 2017 
Anti-TSLP and cat immunotherapy 
  Grade 4 = life-threatening or disabling adverse event 
 Grade 5 = death 
For additional information and a printable version of the NCI-CTCAE manual, go to 
http://ctep.cancer.gov/reporting/ctc.html    
8.4.2 Attribution Definitions 
Adverse events will be categorized for their relation to one or more of the following: 
 Study medications:  
o AMG157/AMG 157 placebo  
o Cat immunotherapy/Cat immunotherapy placebo 
 Study procedures: 
o Nasal allergen challenge 
o Intradermal skin test 
o Skin prick test 
The investigator will make the initial determination of the relation, or attribution, of 
an AE to participation and will record the initial determination on the appropriate 
eCRF and/or SAE reporting form. The relation of an AE to study drug will be 
determined using definitions in the Table 4. Final determination of attribution for 
safety reporting will be decided by [CONTACT_73884]/NIAID. 
Table 4: Attribution of adverse events 
Code Descriptor Definition 
Unrelated Category  
1 Unrelated The adverse event is clearly not related. 
2 Unlikely The adverse event is unlikely related. 
Related Categories 
3 Possible The adverse event has a reasonable possibility of being related; 
there is evidence to suggest a causal relationship. 
[ADDRESS_1124076] 14, 2017 
Anti-TSLP and cat immunotherapy 
 8.5 REPORTING SERIOUS ADVERSE EVENTS 
8.5.1 Reporting SAEs to the IND Sponsor  
The following process for reporting an SAE ensures compliance with 21CFR 312 and 
ICH guidelines. After learning that a participant has experienced an SAE, the 
principal investigator [INVESTIGATOR_811648] (SAE eCRF) within [ADDRESS_1124077] 
include: 
 AE term 
 Study drug treatment 
 Relationship to study medications 
 Reason why the event is serious 
 Supplementary CRF pages must be current at the time of SAE reporting: medical 
history, concomitant medications, demographics, study drug administration, 
death.  
As additional details become available, the SAE eCRF should be updated and 
submitted. Every time the SAE eCRF is submitted, it should be electronically signed 
by [CONTACT_185546].  
For additional information regarding SAE reporting, contact [CONTACT_93255]: 
Rho Product Safety  
[ADDRESS_1124078] 
Chapel Hill, NC  [ZIP_CODE] 
Toll-free - ([PHONE_1899] 
SAE Fax Line: [PHONE_286] 
Email: [EMAIL_305]  
8.5.[ADDRESS_1124079] report the event to the appropriate health 
authorities using one of these two options: 
 Standard reporting (IND annual report). This option applies if the AE is 
classified as:  
o Serious, expected, suspected adverse reactions described in Section 8.2.2 , 
Section 8.2.3  and Section 8.2.4 . 
o Serious and not a suspected adverse reaction described in Section 8.2.2  and 
Section 8.2.3 . 
 Expedited reporting (IND safety report). This option applies if the AE is 
classified as one of the following: 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124080] 14, 2017 
Anti-TSLP and cat immunotherapy 
 1. Serious and unexpected suspected adverse reaction (S[LOCATION_003]R) per Section 
8.2.2, Section 8.2.[ADDRESS_1124081] a causal relationship 
between the study drug and the adverse event, such as: 
  
 A single occurrence of an event that is uncommon and known to be 
strongly associated with drug exposure (e.g., angioedema, hepatic injury, 
or Stevens-Johnson Syndrome); 
 
 One or more occurrences of an event that is not commonly associated 
with drug exposure, but is otherwise uncommon in the population 
exposed to the drug (e.g., tendon rupture); 
 
 An aggregate analysis of specific events observed in a clinical trial (such 
as known consequences of the underlying disease or condition under 
investigation or other events that commonly occur in the study 
population independent of drug therapy) that indicates those events occur 
more frequently in the drug  treatment group than in a concurrent or 
historical control group. 
 
2. Any findings from other studies: The sponsor must report any findings from 
other epi[INVESTIGATOR_9037], pooled analysis of multiple studies, or clinical 
studies that suggest a significant risk in humans exposed to the drug that 
would result in a safety-related change in the protocol, informed consent, 
investigator brochure, or other aspects of the overall conduct of the study. 
Safety reports must be reported by [CONTACT_73884]/NIAID to the appropriate health authorities 
within 15 calendar days; fatal or immediately life-threatening, serious, unexpected, 
suspected adverse reactions must be reported within [ADDRESS_1124082] report SAEs to their respective IRBs as mandated by 
[CONTACT_476]. 
8.5.3 Reporting SAEs to the DSMB 
The NIAID and ITN will provide the DSMB with data of all SAEs on an ongoing 
basis, including quarterly reports of all SAEs and as indicated in the stoppi[INVESTIGATOR_004]. 
8.5.4 Reporting Pregnancy  
The principal investigator [INVESTIGATOR_811649] 
(EDC) system within [ADDRESS_1124083] 14, 2017 
Anti-TSLP and cat immunotherapy 
 Any pregnancy complication or elective termination of a pregnancy for medical 
reasons will be recorded as an AE or SAE as described in Section 8.3.1  and Section 
8.3.2.  
9 S TATISTICAL CONSIDERATIONS AND ANALYTICAL PLAN 
9.1 ANALYSIS SAMPLES  
Intent to treat (ITT) sample:  All subjects who are randomly assigned to treatment 
or placebo. 
Per protocol (PP) samples:  All ITT sample participants who remain in the study for 
at least [ADDRESS_1124084] be compliant with study medication and study assessments, defined as 
1) The primary TNSS AUC endpoint at 104 weeks is collected, and 2)  Taking 75% 
of their study medication for the duration of the study. Compliance with study 
medication will be as assessed by [CONTACT_811696]: 
-[ADDRESS_1124085] 12 of 16 (≥75%) prescribed SIT doses of 3000+ and 10 of 13 (75%) 
AMG 157 infusions are taken. 
Safety sample (SS) :  All randomized participants who receive at least one dose of 
study medication. Participants in the safety sample will be analyzed with the group 
according to the medication they actually received, regardless of their randomized 
assignment.  
9.[ADDRESS_1124086] 14, 2017 
Anti-TSLP and cat immunotherapy 
 groups: cat immunotherapy plus AMG 157 (group A in Figure 1) and cat 
immunotherapy plus placebo (group B in Figure 1).  
The 0 to 1 hour TNSS AUC will be calculated using the trapezoidal rule. 
A supplementary analysis of the primary endpoint will also be performed using the 
PP sample. 
9.2.3 Secondary Endpoints 
This study is not designed or powered to perform hypothesis testing on secondary 
endpoints. All secondary analyses will be treated as supportive. P-values will be 
presented for the secondary endpoints but will not be adjusted for multiplicity and 
should be interpreted with caution. The secondary endpoints will be analyzed using 
the ITT sample and will include all pairwise comparisons among the four study 
groups. 
Secondary endpoints include measures of allergic response assessed at the timepoints 
listed in Section 3.3.2  including: 
 Skin prick test endpoint titration 
 Skin early phase response (EPR) to intradermal testing 
 Skin late phase response (LPR) to intradermal testing 
 Peak TNSS EPR 
 TNSS EPR 
 TNSS LPR 
 PNIF LPR AUC  
 PNIF EPR AUC  
9.2.4 Exploratory Endpoints 
Exploratory endpoints related to mechanisms of immune modulation and tolerance 
assessed prior to, during and after therapy, including those related to: 
 Local immune response in nasal fluid for inflammatory cytokines. Nasal 
brushing for cells for RNA extraction. 
 Cells in peripheral blood basophil activation at various timepoints during and 
after immunotherapy, cat antigen tetramers for changes during and after 
immunotherapy, cytokine profiles after in vitro cat antigen stimulation. 
 Serum components of cat-specific IgE, IgG and subclasses, IgA inhibition of 
facilitated antigen presentation. 
9.2.[ADDRESS_1124087] 10 participants in each treatment group (30% of the total planned 
sample size) have all reached their week 52 TNSS assessment  
The interim analysis will be performed by a statistician not associated with the study 
team. The data will only be reviewed by [CONTACT_811697]. 
The rationale for the interim analysis is that if there is good evidence for absence of a 
difference between immunotherapy groups and placebo group, the study hypotheses 
as outlined in Section 9.3  is unlikely to be provable. 
Conditional power will be calculated assuming that there will be an observed 
difference in TNSS AUC 0-1 hr at week 52 of 32% comparing: 
 cat immunotherapy plus AMG 157 (Figure 1, group A) to placebo-placebo 
(Figure 1, group D) 
 cat immunotherapy plus placebo (Figure 1, group B) to placebo-placebo (Figure 
1, group D) 
 the combination of cat immunotherapy plus AMG 157 and cat immunotherapy 
plus placebo (Figure 1, groups A and B) to placebo-placebo (Figure 1, group D) 
First, conditional power will be calculated using the originally planned sample size, 
the assumed treatment effect, and the currently observed distribution for the endpoint. 
Second, conditional power will be calculated using the originally planned sample 
size, the currently observed treatment effect, and the currently observed distribution 
for the endpoint. 
If the conditional power is ≥33% for any of the comparisons, that will be taken as 
evidence against futility and as an indication that the trial should proceed.  
If the conditional power is <33% for all the comparisons, that will be taken as 
evidence of futility and consideration will be given to terminating the study based 
upon the recommendation of the DSMB and at the discretion of the ITN and NIH.  
Since the main outcome of the study, tolerance, cannot be measured at week 52, and 
the main comparison for the primary endpoint, which is between groups A and B, is 
not used in the interim analysis, no alpha adjustment will be made for the final 
analysis. 
9.2.[ADDRESS_1124088] 12 months—including the existence of current signs 
and symptoms—will be collected for each body system. 
9.2.8 Use of Medications 
All medications taken by [CONTACT_80968] 30 days 
before enrollment and continuing throughout the study will be collected. All 
medications used will be coded according to the WHO drug dictionary. The number 
and percentage of participants receiving prior and concomitant medications/therapi[INVESTIGATOR_811650]. 
9.[ADDRESS_1124089], the placebo arm (group D) will not show any improvement in TNSS over 
time. At week 52, we assume that the difference in mean TNSS AUC 0-1 hr between 
the active cat immunotherapy groups and placebo (group D) will be approximately 
40%. These assumptions have been observed in previous cat immunotherapy trials. 
We further assume that TNSS AUC will return close to pre-therapy levels in the 
group that receives immunotherapy alone. This is based on the assumption that the 
immunomodulatory effect of approximately [ADDRESS_1124090], and consistent with the overall study hypothesis, we assume that the 
group receiving combination treatment will lead to tolerance and remain relatively 
stable in terms of TNSS from week 52 through week 104. This would demonstrate 
that AMG 157 contributes to the induction of tolerance. 
These assumptions imply a 40% difference in mean TNSS AUC 0-1 hr for the 
primary comparison, which is between cat immunotherapy plus AMG 157 (group A) 
and cat immunotherapy plus placebo (group B).  
Pi[INVESTIGATOR_811651]-allergic subjects 
(Stephen Durham Imperial College London, personal communication). Table [ADDRESS_1124091] size 
for a 40% difference between groups of 1.82. This higher effect size in large measure 
drove the decision to use this AUC period for the primary endpoint. 
Table 5: Sample size estimates based on pi[INVESTIGATOR_811652] 15% dropout 
Parameter Mean SD Diff 
between 
groups Approximate 
Effect Size 
(mean/SD)  80% 
power 90% 
power 80% 
power 90% 
power 
AUC 0-
8h 14.93 7.1 40% 
35% 
30% 
25% 1.26 
1.37 
1.47 
1.58 24 
30 
41 
58 31 
40 
54 
78 29 
36 
49 
69 37 
48 
64 
92 
AUC 0-
6h 13.27 6.2 40% 
35% 
30% 
25% 1.28 
1.39 
1.50 
1.61 23 
29 
39 
56 30 
39 
52 
74 28 
35 
46 
66 36 
46 
62 
88 
AUC 0-
1h 4.56 1.5 40% 
35% 
30% 
25% 1.82 
1.98 
2.13 
2.28 13 
16 
21 
30 16 
21 
28 
39 16 
19 
25 
36 19 
25 
33 
46 
 
Allowing for approximately 15% dropouts, for 90% power to determine this 
treatment effect at a two-sided 0.[ADDRESS_1124092] as small as 32%. 
Repeated measures analysis commonly provides more statistical power than cross-
sectional studies, since the greater total number of observations over all participants 
and time points increases the degrees of freedom available for hypothesis tests. 
Hence, with the current sample size, the power to detect the expected treatment effect 
is anticipated to be greater than 90%. 
9.4 MISSING DATA 
The dropout rate in this study is anticipated to be less than or equal to 15% and to be 
equally distributed among the randomized groups. The primary analysis does not 
require that missing data be imputed. However, any supportive cross-sectional 
analyses of the primary or secondary endpoints for the ITT population will require 
missing data to be imputed. 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124093] as it relates to the causes and consequences of 
missing data. More specific details of the imputation methods and sensitivity 
analyses will be specified in the SAP. Generally, a combination of multiple 
imputation methods for missing data will be used, including for example: regression, 
propensity scoring, and/or Markov chain Monte Carlo methods. 
9.5 REPORTING DEVIATIONS FROM THE ORIGINAL STATISTICAL 
PLAN 
The principal features of both the study design and the plan for statistical data 
analysis are outlined in this protocol and in the statistical analysis plan (SAP). Any 
change in these features requires either a protocol or an SAP amendment, which is 
subject to review by [CONTACT_4318], the study sponsor(s), and the health authorities. 
These changes will be described in the final study report as appropriate. 
10 A CCESS TO SOURCE DATA/DOCUMENTS  
The investigational sites participating in this study will maintain the highest degree of 
confidentiality permitted for the clinical and research information obtained from 
participants in this clinical trial. Medical and research records should be maintained 
at each site in the strictest confidence. However, as a part of the quality assurance and 
legal responsibilities of an investigation, the investigational sites must permit 
authorized representatives of the ITN, sponsor, and health authorities to examine (and 
to copy when required by [CONTACT_1289]) clinical records for the purposes of quality 
assurance reviews, audits, and evaluation of the study safety and progress. Unless 
required by [CONTACT_77915], only the coded identity associated 
with documents or other participant data may be copi[INVESTIGATOR_530] (and any personally 
identifying information must be obscured). Authorized representatives as noted 
above are bound to maintain the strict confidentiality of medical and research 
information that may be linked to identified individuals. The investigational sites will 
normally be notified in advance of auditing visits. 
[ADDRESS_1124094] of the trial, for 
verifying adherence to the protocol, and for confirming the completeness, 
consistency, and accuracy of all documented data. 
The eCRFs will be completed online via a web-based electronic data capture (EDC) 
system that has been validated and is compliant with Part [ADDRESS_1124095] 14, 2017 
Anti-TSLP and cat immunotherapy 
 using SAS® software. Data queries will be issued and resolved within the EDC 
system or SAS®. 
Study staff at the site will enter information into the electronic CRFs, and the data 
will be stored remotely at a central database. Data quality will be ensured through the 
EDC system’s continuous monitoring of data and real-time detection and correction 
of errors. All elements of data entry (i.e., time, date, verbatim text, and the name [CONTACT_100864]) will be recorded in an electronic audit trail to 
allow all changes in the database to be monitored and maintained in accordance with 
federal regulations.  
Study staff will enter data from a study visit on the relevant eCRFs within 3 days 
following the visit or the time when data become available. 
12 E THICAL CONSIDERATIONS AND COMPLIANCE WITH GOOD CLINICAL 
PRACTICE  
12.1 STATEMENT OF COMPLIANCE 
This trial will be conducted in compliance with the protocol, current Good Clinical 
Practice (GCP) guidelines—adopting the principles of the Declaration of Helsinki—
and all applicable regulatory requirements. 
Prior to study initiation, the protocol and the informed consent documents will be 
reviewed and approved by [CONTACT_811698] (IRB). Any amendments to the protocol or consent 
materials must also be approved by [CONTACT_1034], the IRB and submitted to FDA 
before they are implemented. 
12.2 INFORMED CONSENT 
The informed consent form is a means of providing information about the trial to a 
prospective participant and allows for an informed decision about participation in the 
study. All participants (or their legally acceptable representative) must read, sign, and 
date a consent form before participating in the study, taking the study drug, and/or 
undergoing any study-specific procedures. If a participant does not speak and read 
English, the consent materials must be translated into the appropriate language. 
The informed consent form must be updated or revised whenever important new 
safety information is available, whenever the protocol is amended, and/or whenever 
any new information becomes available that may affect participation in the trial. 
A copy of the informed consent will be given to a prospective participant for review. 
The study investigator, in the presence of a witness, will review the consent and 
answer questions. The participant will be informed that participation is voluntary and 
that he/she may withdraw from the study at any time, for any reason. 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124096] 14, 2017 
Anti-TSLP and cat immunotherapy 
 12.3 PRIVACY AND CONFIDENTIALITY 
A participant’s privacy and confidentiality will be respected throughout the study. 
Each participant will be assigned a sequential identification number. This number, 
rather than the participant’s name, will be used to collect, store, and report participant 
information. 
13 P UBLICATION POLICY 
The ITN policy on publication of study results will apply to this study. Authorized 
participants may find details regarding the policy statement on the ITN internet 
website at http://www.immunetolerance.org .  
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124097] 14, 2017 
Anti-TSLP and cat immunotherapy 
 14 REFERENCES  
1. Salo PM, Calatroni A, Gergen PJ, et al. Allergy-related outcomes in relation to serum IgE: results from the 
National Health and Nutrition Examination Survey 2005-2006. The Journal of allergy and clinical 
immunology 2011;127:1226-[ADDRESS_1124098] mite and cat allergen in different indoor environments. 
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 
1994;24:1164-8. 
3. Ingram JM, Sporik R, Rose G, Honsinger R, Chapman MD, Platts-Mills TA. Quantitative assessment of 
exposure to dog (Can f 1) and cat (Fel d 1) allergens: relation to sensitization and asthma among children 
living in Los Alamos, New Mexico. The Journal of allergy and clinical immunology 1995;96:449-56. 
4. Chapman MD, Wood RA. The role and remediation of animal allergens in allergic diseases. The Journal of 
allergy and clinical immunology 2001;107:S414-21. 
5. Corren J, Diaz-Sanchez D, Saxon A, et al. Effects of omalizumab, a humanized monoclonal anti-IgE 
antibody, on nasal reactivity to allergen and local IgE synthesis. Annals of allergy, asthma & immunology : 
official publication of the American College of Allergy, Asthma, & Immunology 2004;93:243-8. 
6. Corren J, Wood RA, Patel D, et al. Effects of omalizumab on changes in pulmonary function induced by 
[CONTACT_811699]. The Journal of allergy and clinical immunology 2011;127:398-405. 
7. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, Blanco-Quiros A. Monoclonal 
antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. 
The Journal of allergy and clinical immunology 1994;93:556-66. 
8. Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ. Clinical efficacy of specific 
immunotherapy to cat dander: a double-blind placebo-controlled trial. Clinical and experimental allergy : 
journal of the British Society for Allergy and Clinical Immunology 1997;27:860-7. 
9. Hedlin G, Graff-Lonnevig V, Heilborn H, et al. Immunotherapy with cat- and dog-dander extracts. V. 
Effects of 3 years of treatment. The Journal of allergy and clinical immunology 1991;87:955-64. 
10. Ewbank PA, Murray J, Sanders K, Curran-Everett D, Dreskin S, Nelson HS. A double-blind, placebo-
controlled immunotherapy dose-response study with standardized cat extract. The Journal of allergy and 
clinical immunology 2003;111:155-61. 
11. Nanda A, O'Connor M, Anand M, et al. Dose dependence and time course of the immunologic response to 
administration of standardized cat allergen extract. The Journal of allergy and clinical immunology 
2004;114:1339-44. 
12. James LK, Durham SR. Update on mechanisms of allergen injection immunotherapy. Clinical and 
experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2008;38:1074-
88. 
13. Calderon MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy 
for respi[INVESTIGATOR_269463]: from meta-analysis to registration and beyond. The Journal of allergy and clinical 
immunology 2011;127:30-8. 
14. Arvidsson MB, Lowhagen O, Rak S. Allergen specific immunotherapy attenuates early and late phase 
reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study. 
Allergy 2004;59:74-80. 
15. Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and 
peripheral IL-10 responses and blocking IgG activity. J Immunol 2004;172:3252-9. 
16. Roan F, Bell BD, Stoklasek TA, Kitajima M, Han H, Ziegler SF. The multiple facets of thymic stromal 
lymphopoietin (TSLP) during allergic inflammation and beyond. Journal of leukocyte biology 
2012;91:877-86. 
17. Zhang Y, Zhou B. Functions of thymic stromal lymphopoietin in immunity and disease. Immunologic 
research 2012;52:211-23. 
18. Kitajima M, Lee HC, Nakayama T, Ziegler SF. TSLP enhances the function of helper type 2 cells. 
European journal of immunology 2011;41:1862-71. 
19. Mou Z, Xia J, Tan Y, et al. Overexpression of thymic stromal lymphopoietin in allergic rhinitis. Acta oto-
laryngologica 2009;129:297-301. 
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124099] 14, 2017 
Anti-TSLP and cat immunotherapy 
 20. Shikotra A, Choy DF, Ohri CM, et al. Increased expression of immunoreactive thymic stromal 
lymphopoietin in patients with severe asthma. The Journal of allergy and clinical immunology 
2012;129:104-[ADDRESS_1124100] inflammation in mice. Nature immunology 2005;6:1047-53. 
22. Miyata M, Hatsushika K, Ando T, et al. Mast cell regulation of epi[INVESTIGATOR_811653]. European journal of immunology 2008;38:1487-92. 
23. Kimura S, Pawankar R, Mori S, et al. Increased expression and role of thymic stromal lymphopoietin in 
nasal polyposis. Allergy, asthma & immunology research 2011;3:186-93. 
24. Bunyavanich S, Melen E, Wilk JB, et al. Thymic stromal lymphopoietin (TSLP) is associated with allergic 
rhinitis in children with asthma. Clinical and molecular allergy : CMA 2011;9:1. 
25. He R, Oyoshi MK, Gariby[CONTACT_1629] L, Kumar L, Ziegler SF, Geha RS. TSLP acts on infiltrating effector T cells to 
drive allergic skin inflammation. Proceedings of the National Academy of Sciences of the [LOCATION_002] of 
America 2008;105:[ZIP_CODE]-80. 
26. Zhang F, Huang G, Hu B, Song Y, Shi Y. A soluble thymic stromal lymphopoietin (TSLP) antagonist, 
TSLPR-immunoglobulin, reduces the severity of allergic disease by [CONTACT_811700]. 
Clinical and experimental immunology 2011;164:256-64. 
27. Wang YH, Ito T, Homey B, et al. Maintenance and polarization of human TH2 central memory T cells by 
[CONTACT_85787]-activated dendritic cells. Immunity 2006;24:827-38. 
28. Lei L, Zhang Y, Yao W, Kaplan MH, Zhou B. Thymic stromal lymphopoietin interferes with airway 
tolerance by [CONTACT_811701]-specific regulatory T cells. J Immunol 2011;186:2254-
61. 
29. Iliev ID, Spadoni I, Mileti E, et al. Human intestinal epi[INVESTIGATOR_811654]. Gut 2009;58:1481-9. 
30. Togias A ea. Nasal Provocation Testing.  Middleton's Allergy: Principles and Practice. 7th ed. London: 
Elsevier; 2009:1281-94. 
31. Scadding GW, Calderon MA, Bellido V, et al. Optimisation of grass pollen nasal allergen challenge for 
assessment of clinical and immunological outcomes. Journal of immunological methods 2012;384:25-32. 
32. Nicholson GC, Kariyawasam HH, Tan AJ, et al. The effects of an anti-IL-13 mAb on cytokine levels and 
nasal symptoms following nasal allergen challenge. The Journal of allergy and clinical immunology 
2011;128:800-[ADDRESS_1124101] (Standard Cat Hair) [Package Insert]. ALK-Abello, Inc Port Washington, NY October 
2008. 
34. Worm M, Lee HH, Kleine-Tebbe J, et al. Development and preliminary clinical evaluation of a peptide 
immunotherapy vaccine for cat allergy. The Journal of allergy and clinical immunology 2011;127:89-97,  
e1-14. 
35. Vosshenrich CA, Cumano A, Muller W, Di Santo JP, Vieira P. Thymic stromal-derived lymphopoietin 
distinguishes fetal from adult B cell development. Nature immunology 2003;4:773-9. 
36. Yoo J, Omori M, Gyarmati D, et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic 
stromal lymphopoietin transgene specifically in the skin. The Journal of experimental medicine 
2005;202:541-9. 
37. Harada M, Hirota T, Jodo AI, et al. Functional analysis of the thymic stromal lymphopoietin variants in 
human bronchial epi[INVESTIGATOR_1663]. American journal of respi[INVESTIGATOR_389037] 2009;40:368-
74. 
38 Hamida Hammad et al. Inflammatory dendritic cells—not basophils—are necessary and sufficient for 
induction of Th2 immunity to inhaled house dust mite allergen. 2010 J Exp Med 207 (10):[ADDRESS_1124102] 14, 2017 
Anti-TSLP and cat immunotherapy 
 APPENDIX 1 SCHEDULE OF EVENTS:  SCREENING AND UPDOSING  
 Screening  Baseline                 
Day -28 -14 0 1 8 15 22 28 29 36 43 50 56 57 64 71 78  
Week -4 -2 0 0 1 2 3 4 4 5 6 7 8 8 9 10 11  
Visit -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 UN 
General Assessments                    
Informed consent X                  
Medical history X                  
Allergy history X                  
Comprehensive physical exam X                  
Limited physical exam   X               X 
Vital signs X  X     X     X     X 
Pulmonary function testing 
(spi[INVESTIGATOR_038])  X X                 
Pre and post peak flow testing X X  X X X X  X X X X  X X X X  
Adverse events X X X X X X X X X X X X X X X X X X 
Concomitant medications X X X X X X X X X X X X X X X X X X 
Cat exposure level X  X     X     X      
Clinical Assessments                    
Screening nasal allergen 
challenge  X                  
Nasal allergen challenge  X                 
Total nasal symptom score X X                 
Peak nasal inspi[INVESTIGATOR_10229] X X                 
Intradermal skin test  X                 
Skin prick test cat allergen X                  
Skin prick test serial titration   X   X   X           
ECG X                  
Study Medication                    
Randomization   X                
AMG [ADDRESS_1124103] X  X     X     X      
Hematology X  X                
Comprehensive chemistry X  X                
QuantiFERON® TB testing X                  
HIV antibody  X                  
Hepatitis B surface antigen X                  
Hepatitis C antibody X                  
Creatinine clearance  X  X                
Immune Tolerance Network CONFIDENTIAL Page [ADDRESS_1124104] 14, 2017 
Anti-TSLP and cat immunotherapy 
  Screening  Baseline                 
Day -28 -14 0 1 8 15 22 28 29 36 43 50 56 57 64 71 78  
Week -4 -2 0 0 1 2 3 4 4 5 6 7 8 8 9 10 11  
Visit -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 UN 
Pharmacokinetics and 
Antibody Assessments                   
Anti-AMG 157 antibody   X     X           
AMG 157 pharmacokinetics   X     X           
Mechanistic Laboratory 
Assessments                   
Nasal fluid cytokines  X                 
Nasal brushing  X                 
PBMC  X                 
ImmunoCAP for multiple 
allergens X                  
IgG  X                 
IgA  X                 
Total IgE  X                 
Cat-specific IgE  X                 
Serum (FAB and other assays)  X                 
Whole-blood DNA-HLA 
genotypes  X                  
CD154 Assays  X1                 
Whole blood RNA expression  X                 
 
 
 
                                                           
[ADDRESS_1124105] 14, 2017 
Anti-TSLP and cat immunotherapy 
  
APPENDIX 2 SCHEDULE OF EVENTS:  MAINTENANCE 
 
Day 84 85 92 99 112 113 127 140 141 168 169 182 196 224 252 280 308 336  
Week 12 12 13 14 16 16 18 20 20 24 24 26 28 32 36 40 44 48  
Visit 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 UN 
General Assessments                     
Informed consent                    
Medical history                    
Allergy history                    
Comprehensive physical 
exam                    
Limited physical exam                   X 
Vital signs X    X   X  X   X X X X X X X 
Pulmonary function 
testing (spi[INVESTIGATOR_038])             X        
Pre and post peak flow 
testing  X X X  X X  X  X X X X X X X X  
Adverse events X X X X X X X X X X X X X X X X X X X 
Concomitant medications X X X X X X X X X X X X X X X X X X X 
Cat exposure level X    X   X  X   X X X X X X  
Clinical Assessments                     
Screening  nasal allergen 
challenge                     
Nasal allergen challenge             X        
Total nasal symptom 
score            X        
Peak nasal inspi[INVESTIGATOR_17175]            X        
Intradermal skin test             X        
Skin prick test cat 
allergen                     
Skin prick test serial 
titration   X           X        
Study Medication                     
Randomization                     
AMG [ADDRESS_1124106] 14, 2017 
Anti-TSLP and cat immunotherapy 
 Day 84 85 92 99 112 113 127 140 141 168 169 182 196 224 252 280 308 336  
Week 12 12 13 14 16 16 18 20 20 24 24 26 28 32 36 40 44 48  
Visit 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 UN 
Pharmacokinetics and 
Antibody Assessments                     
Anti-AMG 157 antibody              X       
AMG 157 
pharmacokinetics              X       
Mechanistic Laboratory 
Assessments                     
Nasal fluid cytokines             X        
Nasal brushing                     
PBMC X           X        
IgG X           X        
IgA X           X        
Total IgE  X           X        
Cat-specific IgE  X           X        
Serum (FAB and other 
assays) X           X        
Whole-blood DNA-HLA 
genotypes                     
CD154 Assays X2           X2        
Whole blood RNA 
expression  X           X        
 
 
 
                                                           
[ADDRESS_1124107] 14, 2017 
Anti-TSLP and cat immunotherapy 
 APPENDIX 3 SCHEDULE OF EVENTS:  OBSERVATION 
Day 365  421 477  547  617 673 729   
Week 52 60  68 78 88 96 104   
Visit 33 34 35 36 37 38 39 UN Early 
Termination 
General Assessments           
Informed consent          
Medical history          
Allergy history          
Comprehensive physical exam          
Limited physical exam X   X   X X X 
Vital signs X   X   X X  
Pulmonary function testing (spi[INVESTIGATOR_038]) X   X   X   
Pre and post peak flow testing X   X   X   
Adverse events X X3 X3 X X3 X3 X X X 
Concomitant medications X X3 X3 X X3 X3 X X X 
Cat exposure level X X3 X3 X X3 X3 X  X 
Clinical Assessments           
Screening  nasal allergen challenge           
Limited Nasal Allergen Challenge     X      
Nasal allergen challenge  X      X   
Total nasal symptom score  X   X   X   
Peak nasal inspi[INVESTIGATOR_10229]  X   X   X   
Intradermal skin test  X      X   
Skin prick test cat allergen          
Skin prick test serial titration  X   X   X   
Study Medication           
Randomization           
AMG [ADDRESS_1124108] 14, 2017 
Anti-TSLP and cat immunotherapy 
  
Day 365  421 477  547  617 673 729   
Week 52 60  68 78 88 96 104   
Visit 33 34  35 36  37  38  39 UN Early 
Termination 
Pharmacokinetics and Antibody 
Assessments           
Anti-AMG 157 antibody  X      X  X 
AMG 157 pharmacokinetics  X      X  X 
Mechanistic Laboratory Assessments           
Nasal fluid cytokines  X      X   
Nasal brushing  X      X   
PBMC X   X   X   
IgG X   X   X   
IgA X   X   X   
Total IgE  X   X   X   
Cat-specific IgE  X   X   X   
Serum (FAB and other assays) X   X   X   
Whole-blood DNA-HLA genotypes          
CD154 Assays X4   X4   X4   
Whole blood RNA expression X   X   X   
 
 
                                                           
[ADDRESS_1124109] 14, 2017 
Anti-TSLP and cat immunotherapy 
 APPENDIX 4: WORLD ALLERGY ORGANIZATION SUBCUTANEOUS 
IMMUNOTHERAPY SYSTEMIC REACTION GRADING SYSTEM 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Symptom(s)/ sign(s) 
of one organ system 
presenti Symptom(s)/ sign(s) 
of more than 
one organ system 
present Lower respi[INVESTIGATOR_811655] (e.g., 40% 
PEF or FEV1 drop, 
NOT responding to 
an inhaled 
bronchodilator)  Lower or Upper 
respi[INVESTIGATOR_811656], 
urticaria, flushing or 
sensation of heat or 
warmthii Lower respi[INVESTIGATOR_811655]: cough, 
wheezing, shortness 
of breath (e.g., less 
than 40% PEF or 
FEV1 drop, 
responding 
to an inhaled 
bronchodilator)  Upper respi[INVESTIGATOR_811657], uvula or 
tongue edema with 
or without stridor Cardiovascular 
Hypotension with or 
without loss of 
consciousness  
or or    
Upper respi[INVESTIGATOR_811658] (e.g., 
sneezing, rhinorrhea, 
nasal pruritus and/or 
nasal congestion)  Gastrointestinal 
Abdominal cramps, 
vomiting, or 
diarrhea    
 or    
Throat-clearing 
(itchy throat)  Other 
Uterine cramps     
or     
Cough perceived to 
come from the upper 
airway, not the lung, 
larynx, or trachea      
or     
Conjunctival 
Conjunctival 
erythema, pruritus or 
tearing     
     
Other 
Nausea, metallic 
taste, or headache      
 
Patients may also have a feeling of impending doom, especially in grades 2, 3, or 4. 
Note: children with anaphylaxis seldom convey a sense of impending doom and their behavior changes may be a 
sign of anaphylaxis, e.g., becoming very quiet or irritable and cranky. 
Scoring includes a suffix that denotes if and when epi[INVESTIGATOR_811659](s)/sign(s) of the SR: a, ≤ 5 minutes; b, >5 minutes to ≤10 minutes; c, >10 to ≤ 20 minutes; d, >20 
minutes; z, epi[INVESTIGATOR_811660]. 
 
The final grade of the reaction will not be determined until the event is over, regardless of the medication 
administered. 
 
The final report should include the first symptom(s)/sign(s) and the time of onset after the subcutaneous allergen 
immunotherapy injectioniii and a suffix reflecting if and when epi[INVESTIGATOR_811661], e.g., Grade 
2a; rhinitis:[ADDRESS_1124110] 14, 2017 
Anti-TSLP and cat immunotherapy 
  
i. Each Grade is based on organ system involved and severity. Organ systems are defined as: cutaneous, 
conjunctival, upper respi[INVESTIGATOR_696], lower respi[INVESTIGATOR_696], gastrointestinal, cardiovascular and other. A reaction from a 
single organ system such as cutaneous, conjunctival, or upper respi[INVESTIGATOR_696], but not asthma, gastrointestinal, or 
cardiovascular is classified as a Grade 1. Symptom(s)/sign(s) from more than one organ system or asthma, 
gastrointestinal, or cardiovascular are classified as Grades 2 or 3. Respi[INVESTIGATOR_811662], with or 
without loss of consciousness, defines Grade 4 and death Grade 5.The Grade is determined by [CONTACT_099]’s 
clinical judgment. 
ii. This constellation of symptoms may rapi[INVESTIGATOR_14274] a more severe reaction. 
iii. Symptoms occurring within the first minutes after the injection may be a sign of severe anaphylaxis. Mild 
symptoms may progress rapi[INVESTIGATOR_811663]. 
iv. If signs or symptoms are not included in the Table or the differentiation between an SR and vasovagal 
(vasodepressor) reaction, which may occur with any medical intervention, is difficult, please include comment, as 
appropriate. 
 
From: Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy 
Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 
2010;125:569-74, 74 e1-74 e7  